RayKnowChina Research Map
Shortlist

ShanghaiFudan University

Zhongshan Hospital, Fudan University

复旦大学附属中山医院

Listed for 27 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongshan Hospital, Fudan University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌56 papers led8 open trials led
  3. Hepatocellular carcinoma肝细胞癌408 papers led16 open trials led
  4. Stomach cancer胃癌134 papers led8 open trials led
  5. Hepatoblastoma肝母细胞瘤3 papers led
  6. Chordoma脊索瘤0 papers led
  7. Osteosarcoma骨肉瘤5 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤28 papers led
  9. Neuroblastoma神经母细胞瘤0 papers led
  10. Ewing sarcoma尤文肉瘤2 papers led
  11. Multiple myeloma多发性骨髓瘤23 papers led4 open trials led
  12. Beta thalassaemiaβ 地中海贫血1 paper led
  13. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
  14. IgG4-related diseaseIgG4相关性疾病4 papers led
  15. Myasthenia gravis重症肌无力1 paper led1 open trial led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  17. Takayasu arteritis大动脉炎33 papers led2 open trials led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  19. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
  21. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  22. Behçet disease白塞病2 papers led
  23. IgA nephropathyIgA 肾病4 papers led
  24. Osteogenesis imperfecta成骨不全症1 paper led
  25. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  26. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  27. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

10 hospitals in Shanghai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06228079

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

  2. Recruiting
    Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    Phase
    Phase 3
    Started
    2024-07
    Registry
    NCT06235203

    Age 18 years to 75 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan University; 6 listed hospitals as study sitesFuzhou, Nanning, Shanghai, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesInduction / concurrent chemotherapyImaging & AIRadiotherapy technique
Departments in papersENT / head & neck surgeryRadiology / nuclear medicine
Papers it led3
  1. Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma.2025Anti-cancer drugs
  2. A head-to-head comparison of 18F-FDG PET/CT and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma under different disease settings.2024Hellenic journal of nuclear medicine
  3. Effect of Nutritional Intervention on the Management of Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma.2024Nutrition and cancer
All its trials on ClinicalTrials.gov, any status7
  1. Adjuvant vs Surgery Only in Early-stage Recurrent NPCRecruitingNCT06228079Study sitePhase 3Start 2024-06
  2. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPCRecruitingNCT06235203Study sitePhase 3Start 2024-07
  3. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPCStatus unknownNCT05350891Study sitePhase 2Start 2022-05
  4. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05011227Study sitePhase 2Start 2021-08
  5. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  6. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  7. Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAActive, not recruitingNCT02135042Study sitePhase 2/Phase 3Start 2014-07
More papers found outside PubMed (not counted)1
  1. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.2022Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 56 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
56
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 5520222023: 121220232024: 141420242025: 16162025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07054086

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07317609

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  3. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

  4. Recruiting
    Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT07266493

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  5. Recruiting
    Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2022-03
    Registry
    NCT04973306

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  6. Recruiting
    Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT05740995

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  7. Not yet recruiting
    An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07770672

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  8. Not yet recruiting
    Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05420480

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  9. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsNeoadjuvant & combined treatmentSurgery
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led56
  1. RCN2 facilitates esophageal squamous cellular carcinoma metastasis and cisplatin resistance through UBR5-mediated PPP2CA ubiquitination and degradation.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  2. Total-Body PET/CT Metabolic Response in Esophageal Squamous Cell Carcinoma.2026Seminars in nuclear medicine
  3. Positive Lymph Node Status Before and After Neoadjuvant Chemoradiotherapy Improves Prediction of Disease-Free Survival in Esophageal Squamous Cell Carcinoma Patients.2025Annals of surgical oncology
  4. Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  5. Suppressing SENP1 inhibits esophageal squamous carcinoma cell growth via SIRT6 SUMOylation.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  6. Hypoxia-induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9-mediated GSK3β/β-catenin signalling.2025Clinical and translational medicineFree full text
  7. ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.2025Clinical and translational medicineFree full text
  8. Individual risk stratification to predict metastasis for ESD of superficial esophageal squamous cell carcinoma.2025Esophagus : official journal of the Japan Esophageal Society
  9. Primary Tumour Burden Score: A Novel Staging Parameter for Oesophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.2025European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  10. [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.2025European journal of nuclear medicine and molecular imaging
  11. SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB-SLC1A3 Axis.2025Frontiers in bioscience (Landmark edition)
  12. Unravelling the difference of immune microenvironment characteristics between esophageal basaloid squamous cell carcinoma and conventional esophageal squamous cell carcinoma.2025Human pathology
  13. Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring.2025Molecular cancerRCTFree full text
  14. Gram-Negative Microflora Dysbiosis Facilitates Tumor Progression and Immune Evasion by Activating the CCL3/CCL5-CCR1-MAPK-PD-L1 Pathway in Esophageal Squamous Cell Carcinoma.2025Molecular cancer research : MCRFree full text
  15. Tertiary lymphoid structures and clinicopathological characteristics in pT1b Esophageal squamous cell carcinoma.2025Pathology, research and practice
  16. Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression.2025Science translational medicine
  17. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma.2025The Journal of thoracic and cardiovascular surgery
  18. FGFR3 amplification is predictive of poor prognosis in esophageal squamous cell carcinoma patients.2025Virchows Archiv : an international journal of pathology
  19. ELF4 contributes to esophageal squamous cell carcinoma growth and metastasis by augmenting cancer stemness via FUT9.2024Acta biochimica et biophysica SinicaFree full text
  20. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.2024Annals of surgical oncology
  21. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.2024Annals of surgical oncology
  22. Development of a TLR-Based Model That Can Predict Prognosis, Tumor Microenvironment, and Drug Response for Esophageal Squamous Cell Carcinoma.2024Biochemical genetics
  23. PPP1r18 promotes tumor progression in esophageal squamous cell carcinoma by regulating the calcineurin-mediated ERK pathway.2024Carcinogenesis
  24. Suppression of SENP3 enhances macrophage alternative activation by mediating IRF4 de-SUMOylation in ESCC progression.2024Cell communication and signaling : CCSFree full text
  25. Genomic profiling and associated B cell lineages delineate the efficacy of neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma.2024EBioMedicineFree full text
  26. Abnormal p16 expression and prognostic significance in esophageal squamous cell carcinoma.2024Histology and histopathology
  27. Machine learning to predict lymph node metastasis in T1 esophageal squamous cell carcinoma: a multicenter study.2024International journal of surgery (London, England)Free full text
  28. Proteomic characterization of esophageal squamous cell carcinoma response to immunotherapy reveals potential therapeutic strategy and predictive biomarkers.2024Journal of hematology & oncologyFree full text
  29. Expression of SOX4 Significantly Predicts the Risk of Lymph Node Metastasis for Patients With Early-Stage Esophageal Squamous Cell Carcinoma.2024Laboratory investigation; a journal of technical methods and pathology
  30. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.2024Nature communicationsFree full text
  31. Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma.2024Scandinavian journal of gastroenterology
  32. miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway.2024Thoracic cancerFree full text
  33. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.2023Annals of oncology : official journal of the European Society for Medical OncologyRCT
  34. Development and Validation of PET/CT-Based Nomogram for Preoperative Prediction of Lymph Node Status in Esophageal Squamous Cell Carcinoma.2023Annals of surgical oncology
  35. PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway/ferroptosis.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  36. Prognostic significance of CCND1 amplification/overexpression in smoking patients with esophageal squamous cell carcinoma.2023Cancer genetics
  37. PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism.2023Cancer research
  38. Prognostic significance of CDK6 amplification in esophageal squamous cell carcinoma.2023Cancer treatment and research communications
  39. Single-cell transcriptomic analysis deciphers key transitional signatures associated with oncogenic evolution in human intramucosal oesophageal squamous cell carcinoma.2023Clinical and translational medicineFree full text
  40. A comparative analysis of clinicopathological factors and survival between esophageal basaloid squamous cell carcinoma and conventional esophageal squamous cell carcinoma.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  41. Muscular injury as an independent risk factor for esophageal stenosis after endoscopic submucosal dissection of esophageal squamous cell cancer.2023Gastrointestinal endoscopy
  42. ClusterNet: a clustering distributed prior embedded detection network for early-stage esophageal squamous cell carcinoma diagnosis.2023Medical physics
  43. Integrative proteogenomic characterization of early esophageal cancer.2023Nature communicationsFree full text
  44. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.2023Nature medicineFree full text
  45. NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143.2022Cell communication and signaling : CCSFree full text
  46. CircCDR1 sponges miR-1290 to regulate cell proliferation, migration, invasion, and apoptosis in esophageal squamous cell cancer.2022Cell cycle (Georgetown, Tex.)Free full text
  47. Repeat endoscopic submucosal dissection as salvage treatment for local recurrence of esophageal squamous cell carcinoma after initial endoscopic submucosal dissection.2022Gastrointestinal endoscopy
  48. Simultaneous endoscopic submucosal dissection for synchronous multiple early esophageal squamous cell carcinoma: a propensity score-matched analysis.2022Surgical endoscopy
  49. Weighted Correlation Network Analysis of Cancer Stem Cell-Related Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma.2022Technology in cancer research & treatmentFree full text
  50. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.2021BMC cancerFree full text
  51. Integrative genome-scale analysis of immune infiltration in esophageal carcinoma.2021International immunopharmacology
  52. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.2021JAMA surgeryRCTFree full text
  53. Prognostic value and characterization of NTRK1 variation by fluorescence in situ hybridization in esophageal squamous cell carcinoma.2021Journal of cancer research and clinical oncologyFree full text
  54. Short- and long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell cancer in patients with prior gastrectomy.2021Surgical endoscopy
  55. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.2021The Journal of thoracic and cardiovascular surgery
  56. Comparative study on artificial intelligence systems for detecting early esophageal squamous cell carcinoma between narrow-band and white-light imaging.2021World journal of gastroenterologyFree full text
Chinese-language papers (not in the count)3
  1. [Clinicopathological features and progression of esophageal basaloid squamous cell carcinoma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [The clinicopathological evaluation of neoadjuvant therapy for esophageal squamous cell carcinoma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [PIK3CA copy number gain in esophageal squamous cell carcinoma and its prognostic significance].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status29
  1. Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07054086Lead sponsorStart 2025-03
  2. Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Lead sponsorPhase 1Start 2025-07
  3. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Lead sponsorPhase 2Start 2024-10
  4. Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07266493Lead sponsorPhase 2Start 2023-12
  5. Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant TherapyNot yet recruitingNCT05420480Lead sponsorN/AStart 2022-07
  6. Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCRecruitingNCT04973306Lead sponsorPhase 2/Phase 3Start 2022-03
  7. Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT05740995Lead sponsorStart 2020-12
  8. Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCCCompletedNCT05807542Lead sponsorPhase 2Start 2022-03
  9. Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell CancerStatus unknownNCT05561699Lead sponsorN/AStart 2022-09
  10. Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Lead sponsorPhase 2/Phase 3Start 2022-06
  11. NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNomaStatus unknownNCT04215471Lead sponsorPhase 2Start 2020-02
  12. Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCCCompletedNCT03001596Lead sponsorN/AStart 2017-01
  13. Long-term Outcomes of Superficial Esophageal Squamous Cell CarcinomaStatus unknownNCT02908204Lead sponsorStart 2016-10
  14. Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell CarcinomaCompletedNCT06364566Lead sponsorN/AStart 2010-10
  15. Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell CarcinomaCompletedNCT06256185Lead sponsorN/AStart 2010-01
  16. An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual ImagingNot yet recruitingNCT07770672Lead (inferred)Phase 2Start 2026-08
  17. an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal CancerActive, not recruitingNCT07605663Lead (inferred)Start 2020-01
  18. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Study sitePhase 3Start 2019-09
  19. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  20. Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.Active, not recruitingNCT05043688Study sitePhase 3Start 2021-09
  21. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  22. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  23. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  24. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  25. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02
  26. Robot-assisted Esophagectomy Versus Conventional Thoracoscopic EsophagectomyStatus unknownNCT03094351Study sitePhase 3Start 2017-07
  27. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  28. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  29. A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaStatus unknownNCT00642239Study sitePhase 4Start 2008-04
More papers found outside PubMed (not counted)25
  1. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  2. 1457P Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy2024Annals of Oncologyarticle
  3. 392. MACHINE LEARNING TO PREDICT LYMPH NODE METASTASIS IN T1 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTICENTER STUDY2024Diseases of the Esophagusarticle
  4. 399. LYMPH NODE METASTATIC PATTERNS AND SENTINEL LYMPH NODES FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER DIFFERENT NEOADJUVANT REGIMENS2024Diseases of the Esophagusarticle
  5. 406. EXPLORING THE OPTIMAL TIMING OF MINIMALLY INVASIVE SURGERY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY2024Diseases of the Esophagusarticle
  6. 413. LYMPH NODE MAJOR PATHOLOGIC RESPONSE IS A POTENTIAL PROGNOSTIC FACTOR AFTER NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2024Diseases of the Esophagusarticle
  7. 430. PROGNOSTIC PATTERNS OF LYMPH NODES WITH COMPLETE TREATMENT RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT CHEMOTHERAPY2024Diseases of the Esophagusarticle
  8. 780. NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMORADIOTHERAPY VS NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL CARCINOMA (CSTAGEII-III): A MULTI-CENTER PROSPECTIVE RANDOMIZED CLINICAL TRIAL (ICROSS)2024Diseases of the Esophagusarticle
  9. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  10. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  11. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  12. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.2024Journal of Clinical Oncologyconference-abstract
  13. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  14. Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort.2023Journal of Clinical Oncologyconference-abstract
  15. Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a si2023Journal of Clinical Oncologyconference-abstract
  16. SINGLE-CELL TRANSCRIPTOMIC ANALYSIS DECIPHERS KEY TRANSITIONAL SIGNATURES ASSOCIATED WITH ONCOGENIC EVOLUTION IN HUMAN INTRAMUCOSAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Gastrointestinal Endoscopyarticle
  17. SINGLE-CELL TRANSCRIPTOMIC ANALYSIS DECIPHERS KEY TRANSITIONAL SIGNATURES ASSOCIATED WITH ONCOGENIC EVOLUTION IN HUMAN INTRAMUCOSAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Gastrointestinal Endoscopyarticle
  18. 15P Prediction for pCR after neoadjuvant immunotherapy combined with chemotherapy using single-cell RNA sequencing in patients with locally advanced esophageal squamous cell carcinoma (escc): A single-arm phase II clinical trial2022Immuno-Oncology Technologyarticle
  19. 325. THE ASSOCIATED RISK BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF AP1S1 AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINESE POPULATION2022Diseases of the Esophagusarticle
  20. 380. UTILITY OF PET/CT FOR LYMPH NODE METASTASIS DETECTION IN PT1 EARLY ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  21. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  22. Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma2022Research Squarepreprint
  23. Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma2022Research Squarepreprint
  24. circHIPK3 regulates cell proliferation and migration by sponging microRNA-124 and regulating serine/threonine kinase 3 expression in esophageal squamous cell carcinoma2022Figsharedataset
  25. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma2021Annals of Surgeryarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 408 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 2.8%.

Papers led
408
2021–2025
Trials led
72
any status, ClinicalTrials.gov
Open trials led
16
recruiting or about to
Open trials as a site
25
led by another institution
Papers led per year
2021: 646420212022: 818120222023: 747420232024: 929220242025: 84842025

16 hospitals in Shanghai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 41

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT06794073

    Age 18 years to 80 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328009

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  3. Recruiting
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07536789

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  4. Recruiting
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    Phase
    Phase 2/Phase 3
    Started
    2025-02
    Registry
    NCT06796803

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai

  5. Recruiting
    HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06860490

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  6. Recruiting
    Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07047586

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  7. Recruiting
    Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07100392

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  8. Recruiting
    TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100405

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  9. Recruiting
    Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07147101

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  10. Recruiting
    Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07227012

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  11. Recruiting
    Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06382103

    Age not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  12. Recruiting
    Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06537908

    Age 18 years to 90 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  13. Recruiting
    Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT06870942

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  14. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  15. Not yet recruiting
    NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07919717

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  16. Not yet recruiting
    A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06935175

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  17. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  18. Recruiting
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07490262

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  19. Recruiting
    A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07521852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai

  20. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  21. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  22. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  23. Recruiting
    A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT06986785

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  24. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  25. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  26. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  27. Recruiting
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06349980

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  28. Recruiting
    HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06515314

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  29. Recruiting
    A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05489289

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  30. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  31. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  32. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  33. Not yet recruiting
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07392866

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  34. Not yet recruiting
    A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07682272

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  35. Not yet recruiting
    A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-11
    Registry
    NCT07691762

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  36. Not yet recruiting
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07823348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  37. Not yet recruiting
    Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07861425

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  38. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  39. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  40. Not yet recruiting
    A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07239986

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai

  41. Not yet recruiting
    A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Registry
    NCT05976568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicineRadiation oncology
Papers it led408
  1. DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Application of targeted deep sequencing for management of hepatocellular carcinoma in a real-world setting: prediction of MRD and adjuvant lenvatinib response.2026Cancer letters
  3. Hypoxia-related CircARSB Modulates lipid metabolism and innate immune crosstalk to influence immune checkpoint inhibitor response in hepatocellular carcinoma.2026Cancer letters
  4. Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy.2026Clinics and research in hepatology and gastroenterology
  5. Combined therapy with microwave ablation and conventional transarterial chemoembolization for hepatocellular carcinoma tumors larger than five centimetres: a prospective study.2026Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  6. Quantitative sonazoid contrast-enhanced ultrasound features for predicting microvascular invasion of hepatocellular carcinoma.2026European journal of radiology
  7. LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.2026European radiology
  8. The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC.2026Hepatology (Baltimore, Md.)Free full text
  9. CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis.2026Hepatology (Baltimore, Md.)
  10. Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.2026International journal of cancerFree full text
  11. Dynamic contrast-enhanced ultrasound with quantitative analysis optimizes LI-RADS for hepatocellular carcinoma diagnosis: a multicenter study.2026Journal of medical ultrasonics (2001)
  12. Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial.2026Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  13. Integrating Contrast-Enhanced Ultrasound Features and Serum Biomarkers in an Online Tool Optimizes Noninvasive Hepatocellular Carcinoma Diagnosis.2026Ultrasound in medicine & biology
  14. miR-32-5p suppresses the progression of hepatocellular carcinoma by regulating the GSK3β/NF-κB signaling.2025Acta biochimica et biophysica SinicaFree full text
  15. Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor-associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  16. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  17. Lactylation-Driven NUPR1 Promotes Immunosuppression of Tumor-Infiltrating Macrophages in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  18. Comprehensive Characterization of Atypical Serum Albumin N-Glycosylation Reveals Hepatocellular Carcinoma Diagnostic Biomarkers.2025Analytical chemistry
  19. ChatExosome: An Artificial Intelligence (AI) Agent Based on Deep Learning of Exosomes Spectroscopy for Hepatocellular Carcinoma (HCC) Diagnosis.2025Analytical chemistry
  20. Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  21. Habitat-derived radiomics analysis based on dual lesion for the prediction of microvascular invasion in bifocal hepatocellular carcinoma.2025BMC medical imagingFree full text
  22. Enhanced diagnostic performance for subcentimeter hepatocellular carcinoma using a novel criterion integrating serum AFP levels and gadolinium-based contrast-enhanced MRI features.2025BMC medical imagingFree full text
  23. Development of a novel diagnostic model integrating microRNAs and GALAD for HBV-related hepatocellular carcinoma.2025Biomarkers in medicineFree full text
  24. Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis.2025Cancer biology & medicineFree full text
  25. Assessment of intrahepatic cholangiocarcinoma with LI-RADS in the high-risk population: MRI diagnosis and postoperative survival.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  26. Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  27. LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation.2025Cancer letters
  28. ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis.2025Cancer research
  29. Targeting MED23 inhibits hepatocellular carcinoma development by suppressing compensatory proliferation and facilitating ROS-mediated cell death.2025Cell death & diseaseFree full text
  30. SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  31. tRF-3a-Pro: A Transfer RNA-Derived Small RNA as a Novel Biomarker for Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma.2025Cell proliferationFree full text
  32. CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma.2025Cell reports. MedicineFree full text
  33. Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.2025Cell research
  34. Targeting MORF4L1-mediated DNA repair potentiates RT-induced antitumor immunity via cGAS-STING activation in hepatocellular carcinoma.2025Cellular & molecular immunology
  35. Prognostic value of tumor microenvironment-based molecular subtypes in hepatocellular carcinoma patients undergoing surgery for spinal metastases: refining conventional scoring systems.2025Clinical and experimental medicineFree full text
  36. Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.2025Clinical and molecular hepatologyFree full text
  37. Metabolic enzyme PFKFB3 mediates matrix stiffness-potentiated tumour growth and radiotherapeutic resistance in HCC.2025Clinical and translational medicineFree full text
  38. Lysine-specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti-programmed death 1 therapy in liver cancer.2025Clinical and translational medicineFree full text
  39. Personalized MRD Assessment in Perisurgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  40. Landscape analysis of m5C modification regulators unveils DNMT1-mediated dysregulated pyrimidine metabolism in hepatocellular carcinoma.2025Clinical epigeneticsFree full text
  41. Diagnostic value of contrast-enhanced ultrasound in serum biomarker negative hepatocellular carcinoma and colorectal cancer liver metastasis.2025Clinical hemorheology and microcirculation
  42. Circulating tumor DNA in peripheral blood may predict the efficacy of immune-targeted therapy in patients with hepatocellular carcinoma.2025Clinics and research in hepatology and gastroenterology
  43. Bismuth-based mesoporous nanoball carrying sorafenib for synergistic photothermal and molecularly-targeted therapy in an orthotopic hepatocellular carcinoma xenograft mouse model.2025Colloids and surfaces. B, Biointerfaces
  44. Construction of a Cancer Stem Cell related Histone Acetylation Regulatory Genes Prognostic Model for Hepatocellular Carcinoma via Bioinformatics Analysis: Implications for Tumor Chemotherapy and Immunity.2025Current stem cell research & therapy
  45. Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Free full text
  46. MRI-based predictive model with obesity metabolic phenotype for postoperative survival in HBV-related hepatocellular carcinoma.2025European journal of radiology
  47. Preoperative identification of hepatocellular carcinoma from focal liver lesions ≤ 20 mm in high-risk patients using clinical and contrast-enhanced ultrasound features.2025European journal of radiology
  48. 3D-CEUS/MRI-CEUS fusion imaging vs 2D-CEUS after locoregional therapies for hepatocellular carcinoma: a multicenter prospective study of therapeutic response evaluation.2025European radiologyRCT
  49. Matrix Stiffness Promotes Invasion and Metastasis of Hepatocellular Carcinoma via a New Mechanoresponsive SCD1/HMMR Pathway.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  50. Serum Galectin-9 mirrors immune-evasive microenvironment and predicts early recurrence in hepatocellular carcinoma.2025Gene
  51. Safety and efficacy of hypofractionated radiotherapy combined with tyrosine kinase inhibitors in patients with lung metastases after liver transplantation for hepatocellular carcinoma.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  52. Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.2025Hepatology (Baltimore, Md.)Free full text
  53. LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.2025Hepatology (Baltimore, Md.)
  54. Cordycepin mediates pyroptosis in HCC through the upregulation of TXNIP and synergizes with anti-PD-L1 immunotherapy.2025Hepatology communicationsFree full text
  55. Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?2025Hepatology international
  56. Predictive value of neutrophil-to-lymphocyte ratio in recurrent HCC after repeat hepatectomy or salvage liver transplantation.2025Hepatology international
  57. ALOXE3 transcriptionally regulated by activating transcription factor 3 promotes HCC ferroptosis via ERK and JNK signaling pathway.2025International immunopharmacology
  58. Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway.2025International journal of biological sciencesFree full text
  59. Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.2025International journal of cancer
  60. External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial.2025International journal of radiation oncology, biology, physicsRCT
  61. Sequential HAIC-TACE combined with targeted and immunotherapy in hepatocellular carcinoma: a quality improvement study.2025International journal of surgery (London, England)Free full text
  62. Immunometabolite L-2-HG promotes epigenetic modification of exhausted T cells and improves antitumor immunity.2025JCI insightFree full text
  63. Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib.2025Journal for immunotherapy of cancerFree full text
  64. FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  65. Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.2025Journal for immunotherapy of cancerFree full text
  66. Low-intensity pulsed ultrasound affects proliferation and migration of human hepatocellular carcinoma cells.2025Journal of cancer research and clinical oncologyFree full text
  67. Fluorescent Probes Targeting Acyl-CoA Synthetase Long-Chain Family Member 4 for Intraoperative Imaging of Hepatocellular Carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  68. Patients with hepatocellular carcinoma with triple-positive tumor markers may benefit from postsurgery adjuvant treatment.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  69. The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study.2025Journal of hematology & oncologyFree full text
  70. The Association Between Tumor Radiomic Analysis and Peritumor Habitat-Derived Radiomic Analysis on Gadoxetate Disodium-Enhanced MRI With Microvascular Invasion in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRI
  71. GlyTrait: A Versatile Bioinformatics Tool for Glycomics Analysis.2025Journal of proteome research
  72. SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma.2025Journal of translational medicineFree full text
  73. Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.2025Journal of translational medicineRCTFree full text
  74. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.2025Lancet (London, England)RCT
  75. Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial.2025Liver international : official journal of the International Association for the Study of the LiverRCTFree full text
  76. P53 status combined with MRI findings for prognosis prediction of single hepatocellular carcinoma.2025Magnetic resonance imaging
  77. Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma.2025Nature communicationsFree full text
  78. Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.2025Nature communicationsFree full text
  79. Metabolism archetype cancer cells induce protumor TREM2+ macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.2025Nature communicationsFree full text
  80. A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma.2025Nature communicationsFree full text
  81. 6-aminonicotinamide, a G6PD inhibitor, mitigates CAPS1 reduction mediated HCC metastasis via ERK and GSK3β signals.2025Neoplasia (New York, N.Y.)Free full text
  82. Targeting JMJD6/PPARγ/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.2025Oncogene
  83. Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  84. MRI-based Intra- and Peritumoral Heterogeneity in Hepatocellular Carcinoma for Microvascular Invasion Prediction and Prognostic Risk Stratification.2025Radiology. Imaging cancerFree full text
  85. Cathepsin S regulates ferroptosis sensitivity in hepatocellular carcinoma through the KEAP1-NRF2 signaling pathway.2025Redox biologyFree full text
  86. Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma.2025Science advancesFree full text
  87. Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma.2025Signal transduction and targeted therapyFree full text
  88. Cross-Referencing Multifluid Metabolic Profiles on Hollow Dodecahedral Nanocages for Enhanced Disease Status Identification.2025Small (Weinheim an der Bergstrasse, Germany)
  89. CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.2025The American journal of surgical pathologyFree full text
  90. Impact of steatotic liver disease on hepatitis B-related hepatocellular carcinoma: MRI manifestation and prognostic potential.2025The British journal of radiology
  91. A preoperative nomogram with MR elastography in identifying cytokeratin 19 status of hepatocellular carcinoma.2025The British journal of radiology
  92. Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis.2025The Journal of biological chemistryFree full text
  93. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.2025The Lancet. OncologyRCT
  94. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.2025The lancet. Gastroenterology & hepatologyRCT
  95. An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma.2025The oncologistFree full text
  96. Contrast-enhanced Ultrasound Features of Primary Hepatic Lymphoma Are Different From Common Malignant Hepatic Tumors: A Comparative Study.2025Ultrasound in medicine & biology
  97. Ras-related protein Rab24 plays a predictive role in hepatocellular carcinoma and enhanced tumor proliferation.2025World journal of gastroenterologyFree full text
  98. Ultrasound findings of hepatic epithelioid hemangioendothelioma: comparison with other malignant hepatic tumors.2024Abdominal radiology (New York)
  99. MRI-based radiomics signature: a potential imaging biomarker for prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma.2024Abdominal radiology (New York)
  100. Association of magnetic resonance imaging-derived sarcopenia with outcomes of patients with hepatocellular carcinoma after hepatectomy.2024Abdominal radiology (New York)
  101. Value of magnetic resonance imaging for diagnosis of LR‑3 and LR-4 lesions coexisting with hepatocellular carcinoma.2024Abdominal radiology (New York)
  102. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features2024Abdominal radiology (New York)
  103. Detecting microvascular invasion in hepatocellular carcinoma using the impeded diffusion fraction technique to sense macromolecular coordinated water.2024Abdominal radiology (New York)
  104. How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?2024Abdominal radiology (New York)
  105. Component prediction in combined hepatocellular carcinoma-cholangiocarcinoma: habitat imaging and its biologic underpinnings.2024Abdominal radiology (New York)
  106. The value of varying diffusion curvature MRI for assessing the microvascular invasion of hepatocellular carcinoma.2024Abdominal radiology (New York)
  107. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2024Abdominal radiology (New York)
  108. Yttrium-90 Transarterial Radioembolization: An Effective Primary or Salvage Therapy to Bridge the Patients with Hepatocellular Carcinoma to Liver Transplantation.2024Academic radiology
  109. Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  110. RECQL4 Inhibits Radiation-Induced Tumor Immune Awakening via Suppressing the cGAS-STING Pathway in Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  111. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.2024BMC genomicsFree full text
  112. Uncovering essential anesthetics-induced exosomal miRNAs related to hepatocellular carcinoma progression: a bioinformatic investigation.2024BMC medical genomicsFree full text
  113. HuR facilitates miR-93-5p-induced activation of MAP3K2 translation via MAP3K2 3'UTR ARE2 in hepatocellular carcinoma.2024Biochemical and biophysical research communications
  114. Targeting non-coding RNAs and N6-methyladenosine modification in hepatocellular carcinoma.2024Biochemical pharmacology
  115. HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition.2024Biochimica et biophysica acta. Molecular cell research
  116. Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma.2024Biomaterials
  117. Peripheral Lymphocytes in Primary Liver Cancers: Elevated NK and CD8+ T Cells and Dysregulated Selenium Metabolism.2024BiomoleculesFree full text
  118. Stratifying ICIs-responsive tumor microenvironment in HCC: from parsing out immune-hypoxic crosstalk to clinically applicable MRI-radiomics models.2024British journal of cancerFree full text
  119. Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study.2024British journal of clinical pharmacology
  120. Effect of Serum Interleukin-6 Concentration on the Prognosis After Radiotherapy for Patients With Hepatocellular Carcinoma.2024Canadian journal of gastroenterology & hepatologyFree full text
  121. Precision treatment in advanced hepatocellular carcinoma.2024Cancer cell
  122. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma.2024Cancer communications (London, England)Free full text
  123. Epidemiological and clinical characteristics of hepatocellular carcinoma in Xiamen.2024Cancer epidemiology
  124. Diffusion-based virtual MR elastography for predicting recurrence of solitary hepatocellular carcinoma after hepatectomy.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  125. Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization.2024Cancer immunology, immunotherapy : CIIFree full text
  126. A synergistic regulation works in matrix stiffness-driven invadopodia formation in HCC.2024Cancer letters
  127. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.2024Cancer letters
  128. Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma.2024Cancer letters
  129. Tumor-associated macrophage-induced circMRCKα encodes a peptide to promote glycolysis and progression in hepatocellular carcinoma.2024Cancer letters
  130. TGF-β1/SMAD3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma.2024Cancer letters
  131. Effective Antiviral Therapy Improves Immunosuppressive Activities in the Immune Microenvironment of Hepatocellular Carcinoma by Alleviating Inflammation and Fibrosis.2024Cancer medicineFree full text
  132. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.2024Cancer research
  133. High-throughput intact Glycopeptide quantification strategy with targeted-MS (HTiGQs-target) reveals site-specific IgG N-glycopeptides as biomarkers for hepatic disorder diagnosis and staging.2024Carbohydrate polymers
  134. BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC.2024Cell death & diseaseFree full text
  135. Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma.2024Cell death & diseaseFree full text
  136. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy.2024Cell reports
  137. SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma.2024Cell researchFree full text
  138. Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma.2024Cellular & molecular immunologyFree full text
  139. DDR2/STAT3 Positive Feedback Loop Mediates the Immunosuppressive Microenvironment by Upregulating PD-L1 and Recruiting MDSCs in Oxaliplatin-Resistant HCC.2024Cellular and molecular gastroenterology and hepatologyFree full text
  140. GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  141. Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  142. Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study.2024Chinese medical journalFree full text
  143. Increased IFN-β indicates better survival in hepatocellular carcinoma treated with radiotherapy.2024Clinical and experimental immunology
  144. Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma.2024Clinical and experimental pharmacology & physiology
  145. JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.2024Clinical and molecular hepatologyFree full text
  146. Single-cell multi-modal chromatin profiles revealing epigenetic regulations of cells in hepatocellular carcinoma.2024Clinical and translational medicineFree full text
  147. Contrast-enhanced ultrasound features of hepatic sarcomatoid carcinoma different from hepatocellular carcinoma.2024Clinical hemorheology and microcirculation
  148. Development of a Combined Oxidative Stress and Endoplasmic Reticulum Stress-Related Prognostic Signature for Hepatocellular Carcinoma.2024Combinatorial chemistry & high throughput screeningFree full text
  149. Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study.2024Current oncology (Toronto, Ont.)Free full text
  150. Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression.2024EBioMedicineFree full text
  151. Preoperative prediction of microvascular invasion in hepatocellular carcinoma using diffusion-weighted imaging-based habitat imaging.2024European radiology
  152. Diagnostic algorithm for subcentimeter hepatocellular carcinoma using alpha-fetoprotein and imaging features on gadoxetic acid-enhanced MRI.2024European radiology
  153. A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features.2024European radiology
  154. Sulfiredoxin-1 promotes the growth of hepatocellular carcinoma by inhibiting TFEB-mediated autophagy and lysosome biogenesis.2024Experimental cell research
  155. Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming.2024Experimental cell research
  156. Dynamic changes of gut microbiota in mouse models of metabolic dysfunction-associated steatohepatitis and its transition to hepatocellular carcinoma.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  157. Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway.2024Hepatology international
  158. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.2024Hepatology internationalFree full text
  159. Activation of Wnt/β-catenin signaling promotes immune evasion via the β-catenin/IKZF1/CCL5 axis in hepatocellular carcinoma.2024International immunopharmacology
  160. Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies.2024International immunopharmacology
  161. Inhibition of SIRT1 relieves hepatocarcinogenesis via alleviating autophagy and inflammation.2024International journal of biological macromolecules
  162. Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma.2024International journal of biological sciencesFree full text
  163. Multi-Omics profiling identifies aldehyde dehydrogenase 2 as a critical mediator in the crosstalk between Treg-mediated immunosuppression microenvironment and hepatocellular carcinoma.2024International journal of biological sciencesFree full text
  164. WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy.2024Journal for immunotherapy of cancerFree full text
  165. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.2024Journal for immunotherapy of cancerFree full text
  166. Effects of the subtypes of apolipoprotein E on immune inhibition and prognosis in patients with Hepatocellular Carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  167. Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis.2024Journal of cancer research and clinical oncologyFree full text
  168. STRN3 promotes tumour growth in hepatocellular carcinoma by inhibiting the hippo pathway.2024Journal of cellular and molecular medicineFree full text
  169. Efficient gene delivery by multifunctional star poly (β-amino ester)s into difficult-to-transfect macrophages for M1 polarization.2024Journal of controlled release : official journal of the Controlled Release Society
  170. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.2024Journal of hepatology
  171. Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy.2024Journal of imaging informatics in medicineFree full text
  172. Evaluate the Microvascular Invasion of Hepatocellular Carcinoma (≤5 cm) and Recurrence Free Survival with Gadoxetate Disodium-Enhanced MRI-Based Habitat Imaging.2024Journal of magnetic resonance imaging : JMRI
  173. MRI for Hepatitis B-Associated Intrahepatic Cholangiocarcinoma: A Multicenter Comparative Study.2024Journal of magnetic resonance imaging : JMRI
  174. Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.2024Journal of medical case reportsFree full text
  175. Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors.2024Journal of translational medicineFree full text
  176. Optimizing of a suitable protocol for isolating tissue-derived extracellular vesicles and profiling small RNA patterns in hepatocellular carcinoma.2024Liver international : official journal of the International Association for the Study of the Liver
  177. A Transformer-Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation.2024Liver international : official journal of the International Association for the Study of the Liver
  178. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts.2024Molecular cancerFree full text
  179. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.2024Oncogene
  180. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.2024OncoimmunologyFree full text
  181. Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway.2024Pharmacological research
  182. Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  183. Activation of NOD1 on tumor-associated macrophages augments CD8+ T cell-mediated antitumor immunity in hepatocellular carcinoma.2024Science advancesFree full text
  184. Multiscale Structured Trimetal Oxide Heterojunctions for Urinary Metabolic Phenotype-Dependent Screening of Early and Small Hepatocellular Carcinoma.2024Small methods
  185. Hepatobiliary-Phase Hypointense Nodules Without Arterial-Phase Hyperenhancement: Developing a Risk Stratification for Hypervascular Transformation Based on a Real-World Observational Cohort Study.2024Technology in cancer research & treatmentFree full text
  186. Identification of SGMS2 as a molecule involved in natural killer cell recruitment and its in-deep analysis in the liver cancer microenvironment: Evidence from large populations cohort.2024The journal of gene medicine
  187. Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy.2024Ultrasound in medicine & biology
  188. Impact of Hepatocellular Carcinoma Tumor Size on Sonazoid Contrast-Enhanced Ultrasound Enhancement Features.2024Ultrasound in medicine & biology
  189. Exosomal microRNAs in hepatocellular carcinoma, expanding research field.2024World journal of gastroenterologyFree full text
  190. Laser-Induced Combinatorial Chemotherapeutic, Chemodynamic, and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal-Organic Frameworks.2023ACS applied materials & interfacesFree full text
  191. Preoperative identification of cytokeratin 19 status of hepatocellular carcinoma based on diffusion kurtosis imaging.2023Abdominal radiology (New York)
  192. Subcentimeter hepatocellular carcinoma (HCC) on gadoxetic-acid-enhanced MRI: less frequent typical imaging features compared to 1-2 cm HCC but better prognosis after surgical resection.2023Abdominal radiology (New York)
  193. Combined early dynamic 18F-FDG PET/CT and conventional whole-body 18F-FDG PET/CT in hepatocellular carcinoma.2023Abdominal radiology (New York)
  194. The added value of 18F-FDG PET/MRI multimodal imaging in hepatocellular carcinoma for identifying cytokeratin 19 status.2023Abdominal radiology (New York)
  195. Distinct radiological features of lymphoepithelioma-like intrahepatic cholangiocarcinoma: comparison with classical intrahepatic cholangiocarcinoma.2023Abdominal radiology (New York)
  196. Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.2023Abdominal radiology (New York)
  197. Radiomics on Gadoxetate Disodium-enhanced MRI: Non-invasively Identifying Glypican 3-Positive Hepatocellular Carcinoma and Postoperative Recurrence.2023Academic radiology
  198. Preoperatively Identify the Microvascular Invasion of Hepatocellular Carcinoma with the Restricted Spectrum Imaging.2023Academic radiology
  199. Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients.2023Acta radiologica (Stockholm, Sweden : 1987)
  200. Synergistic Photochemo Effects Based on Light-Activatable Dual Prodrug Nanoparticles for Effective Cancer Therapy.2023Advanced healthcare materials
  201. Novel Three-Dimensional Hierarchical Porous Carbon Probe for the Discovery of N-Glycan Biomarkers and Early Hepatocellular Carcinoma Detection.2023Analytical chemistry
  202. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.2023Annals of surgical oncologyFree full text
  203. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.2023AutophagyFree full text
  204. Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.2023BMC cancerFree full text
  205. The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE.2023BMC gastroenterologyFree full text
  206. Inhibition of autophagy in macrophage promotes IL-1β-mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  207. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy.2023British journal of cancerFree full text
  208. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.2023Cancer biology & therapyFree full text
  209. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.2023Cancer letters
  210. Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.2023Cancer letters
  211. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.2023Cancer medicineFree full text
  212. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.2023Cell biology and toxicology
  213. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression.2023Cell death & diseaseFree full text
  214. Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis.2023Cell death & diseaseFree full text
  215. Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment.2023Cellular and molecular gastroenterology and hepatologyFree full text
  216. Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma.2023Cellular signalling
  217. Gas7 attenuates hepatocellular carcinoma progression and chemoresistance through the PI3K/Akt signaling pathway.2023Cellular signalling
  218. Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy.2023Clinical & experimental metastasis
  219. Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy.2023Clinical and experimental pharmacology & physiology
  220. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.2023Clinical and molecular hepatologyFree full text
  221. Clinical application of preoperative shear wave dispersion for prediction of post liver failure in patients with hepatocellular carcinoma after hepatectomy.2023Clinical hemorheology and microcirculation
  222. Clinical application of two dimensional shear wave elastography with a propagation map in evaluating liver fibrosis in patients with liver tumors.2023Clinical hemorheology and microcirculation
  223. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway.2023Clinical immunology (Orlando, Fla.)
  224. Quantitative image features of gadoxetic acid-enhanced MRI for predicting glypican-3 expression of small hepatocellular carcinoma ≤3 cm.2023Clinical radiology
  225. Single-cell and spatial architecture of primary liver cancer.2023Communications biologyFree full text
  226. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.2023European radiology
  227. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.2023European radiology
  228. Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis.2023European radiology
  229. Prognostic value of LI-RADS category on MRI in patients with primary hepatic lymphoepithelioma-like carcinoma.2023European radiology
  230. Prognostic factors for long-term outcome in bifocal hepatocellular carcinoma after resection.2023European radiology
  231. Glycoproteomic contributions to hepatocellular carcinoma research: a 2023 update.2023Expert review of proteomics
  232. The Pyroptosis-Related Signature Composed of GSDMC Predicts Prognosis and Contributes to Growth and Metastasis of Hepatocellular Carcinoma.2023Frontiers in bioscience (Landmark edition)
  233. Sublethal heat treatment enhances lactic acid uptake in macrophages via MCT1, leading to reduced paraspeckle formation and a subsequent decrease in macrophage pyroptosis.2023Frontiers in immunologyFree full text
  234. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy.2023Frontiers in immunologyFree full text
  235. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.2023Gastroenterology
  236. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.2023Hepatology (Baltimore, Md.)
  237. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.2023Hepatology (Baltimore, Md.)Free full text
  238. Ten-eleven translocation-2 inactivation restrains IL-10-producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma.2023Hepatology (Baltimore, Md.)
  239. Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA.2023Hepatology international
  240. Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1.2023Hepatology international
  241. Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation.2023Hepatology internationalFree full text
  242. Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma.2023International immunopharmacology
  243. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.2023Journal for immunotherapy of cancerFree full text
  244. Prognosis of spontaneously ruptured hepatocellular carcinoma: a propensity score matching study.2023Journal of cancer research and clinical oncologyFree full text
  245. Increased expression of autophagy-related gene 5 indicates poor prognosis in patients with hepatocellular carcinoma.2023Journal of digestive diseases
  246. IRF5 promotes glycolysis in the progression of hepatocellular carcinoma and is regulated by TRIM35.2023Journal of digestive diseases
  247. Assessment of an MR Elastography-Based Nomogram as a Potential Imaging Biomarker for Predicting Microvascular Invasion of Hepatocellular Carcinoma.2023Journal of magnetic resonance imaging : JMRI
  248. An MRI-Based Prognostic Stratification System for Medical Decision-Making of Multinodular Hepatocellular Carcinoma Patients Beyond the Milan Criteria.2023Journal of magnetic resonance imaging : JMRI
  249. Characterization of Microvascular Invasion in Hepatocellular Carcinoma Using Computational Modeling of Interstitial Fluid Pressure and Velocity.2023Journal of magnetic resonance imaging : JMRI
  250. Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis.2023Journal of translational medicineFree full text
  251. Predicting the recurrence of hepatocellular carcinoma (≤ 5 cm) after resection surgery with promising risk factors: habitat fraction of tumor and its peritumoral micro-environment.2023La Radiologia medica
  252. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.2023La Radiologia medica
  253. Preoperative assessment of microvascular invasion of hepatocellular carcinoma using non-Gaussian diffusion-weighted imaging with a fractional order calculus model: A pilot study.2023Magnetic resonance imaging
  254. Prediction of therapeutic response of advanced hepatocellular carcinoma to combined targeted immunotherapy by MRI.2023Magnetic resonance imaging
  255. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma.2023Nature metabolism
  256. Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro.2023PeerJFree full text
  257. Preliminary radiogenomic study of hepatitis B virus-related hepatocellular carcinoma: associations between MRI features and mutations.2023Personalized medicine
  258. The miR-34a-5p-c-MYC-CHK1/CHK2 Axis Counteracts Cancer Stem Cell-Like Properties and Enhances Radiosensitivity in Hepatocellular Cancer Through Repression of the DNA Damage Response.2023Radiation research
  259. Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis.2023Surgical endoscopy
  260. The Effects of Cinobufagin on Hepatocellular Carcinoma Cells Enhanced by MRT68921, an Autophagy Inhibitor.2023The American journal of Chinese medicine
  261. Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma.2023TheranosticsFree full text
  262. Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.2023Ultrasound in medicine & biology
  263. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.2023World journal of gastroenterologyFree full text
  264. Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma.2022ACS applied materials & interfaces
  265. Contrast-enhanced magnetic resonance imaging perfusion can predict microvascular invasion in patients with hepatocellular carcinoma (between 1 and 5 cm).2022Abdominal radiology (New York)
  266. MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy.2022Academic radiology
  267. Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma.2022Acta biochimica et biophysica SinicaFree full text
  268. TMEM106A transcriptionally regulated by promoter methylation is involved in invasion and metastasis of hepatocellular carcinoma.2022Acta biochimica et biophysica SinicaFree full text
  269. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.2022Acta pharmacologica SinicaFree full text
  270. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.2022Acta radiologica (Stockholm, Sweden : 1987)
  271. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma.2022American journal of surgery
  272. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.2022BJS openFree full text
  273. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.2022BMC cancerFree full text
  274. Exosomal microRNAs in the DLK1-DIO3 imprinted region derived from cancer-associated fibroblasts promote progression of hepatocellular carcinoma by targeting hedgehog interacting protein.2022BMC gastroenterologyFree full text
  275. A novel prognostic model for hepatocellular carcinoma based on 5 microRNAs related to vascular invasion.2022BMC medical genomicsFree full text
  276. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.2022Biochemical and biophysical research communications
  277. Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing.2022Biochimica et biophysica acta. Reviews on cancer
  278. Prediction of programmed cell death protein 1 in hepatocellular carcinoma patients using radiomics analysis with radiofrequency-based ultrasound multifeature maps.2022Biomedical engineering onlineFree full text
  279. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.2022Canadian journal of gastroenterology & hepatologyFree full text
  280. Peripheral naïve CD8+ T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a biomarker study.2022Cancer communications (London, England)Free full text
  281. IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment.2022Cancer discovery
  282. CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma.2022Cancer immunology, immunotherapy : CIIFree full text
  283. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.2022Cancer letters
  284. CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma.2022Cancer research
  285. The spatial distribution of immune cell subpopulations in hepatocellular carcinoma.2022Cancer scienceFree full text
  286. Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma.2022Cellular and molecular gastroenterology and hepatologyFree full text
  287. The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth.2022Cellular oncology (Dordrecht, Netherlands)Free full text
  288. CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.2022Clinical and translational medicineFree full text
  289. Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomics features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study.2022Clinical hemorheology and microcirculation
  290. Baseline and contrast-enhanced ultrasound features of hepatic epithelioid angiomyolipoma.2022Clinical hemorheology and microcirculation
  291. Hepatocellular carcinoma in the non-cirrhotic liver.2022Clinical hemorheology and microcirculation
  292. CT volumetry helps predict prognosis of large hepatocellular carcinoma after resection.2022Clinical radiology
  293. Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study.2022Clinics and research in hepatology and gastroenterology
  294. An Immune-Related Gene Signature Predicting Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  295. First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review.2022Current oncology (Toronto, Ont.)Free full text
  296. Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization.2022Current oncology (Toronto, Ont.)Free full text
  297. BRG1 regulates lipid metabolism in hepatocellular carcinoma through the PIK3AP1/PI3K/AKT pathway by mediating GLMP expression.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  298. Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma.2022Disease markersFree full text
  299. Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma.2022Disease markersFree full text
  300. Differentiating Cytokeratin 19 expression of hepatocellular carcinoma by using multi-b-value diffusion-weighted MR imaging with mono-exponential, stretched exponential, intravoxel incoherent motion, diffusion kurtosis imaging and fractional2022European journal of radiology
  301. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.2022European radiology
  302. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma.2022European radiology
  303. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.2022European radiology
  304. Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma.2022European radiology
  305. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.2022European radiology
  306. Microvascular invasion of small hepatocellular carcinoma can be preoperatively predicted by the 3D quantification of MRI.2022European radiology
  307. Camrelizumab: an investigational agent for hepatocellular carcinoma.2022Expert opinion on investigational drugs
  308. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.2022Frontiers in immunologyFree full text
  309. Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.2022Frontiers in immunologyFree full text
  310. Construction and Validation of an Epigenetic Regulator Signature as A Novel Biomarker For Prognosis, Immunotherapy, And Chemotherapy In Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  311. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  312. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  313. Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  314. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling.2022Gut microbesFree full text
  315. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.2022Hepatology (Baltimore, Md.)
  316. Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma.2022International journal of biological sciencesFree full text
  317. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.2022International journal of radiation oncology, biology, physics
  318. The treatment strategy and outcome for spontaneously ruptured hepatocellular carcinoma: a single-center experience in 239 patients.2022Journal of cancer research and clinical oncologyFree full text
  319. Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/β-catenin axis activity.2022Journal of cellular and molecular medicineFree full text
  320. High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.2022Journal of clinical laboratory analysisFree full text
  321. Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway.2022Journal of experimental & clinical cancer research : CRFree full text
  322. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.2022Journal of hepatology
  323. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.2022Journal of hepatology
  324. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.2022Journal of translational medicineFree full text
  325. lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.2022Journal of translational medicineFree full text
  326. GPM6A expression is suppressed in hepatocellular carcinoma through miRNA-96 production.2022Laboratory investigation; a journal of technical methods and pathology
  327. The E3 ubiquitin ligase SOCS-7 reverses immunosuppression via Shc1 signaling in hepatocellular carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  328. Changing epidemiology of hepatocellular carcinoma in Asia.2022Liver international : official journal of the International Association for the Study of the Liver
  329. Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization.2022Medicina (Kaunas, Lithuania)Free full text
  330. Recurrence Outcome in Hepatocellular Carcinoma within Milan Criteria Undergoing Microwave Ablation with or without Transarterial Chemoembolization.2022Medicina (Kaunas, Lithuania)Free full text
  331. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study.2022Molecular oncologyFree full text
  332. Sphingosine-1-phosphate transporter spinster homolog 2 is essential for iron-regulated metastasis of hepatocellular carcinoma.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  333. An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  334. Modulation of the p38 MAPK Pathway by Anisomycin Promotes Ferroptosis of Hepatocellular Carcinoma through Phosphorylation of H3S10.2022Oxidative medicine and cellular longevityFree full text
  335. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism.2022Redox biologyFree full text
  336. Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence.2022Signal transduction and targeted therapyFree full text
  337. Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction.2022Surgical innovation
  338. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.2022Technology in cancer research & treatmentFree full text
  339. Future liver volume combined with platelet count predicts liver failure after major hepatectomy.2022The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  340. ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.2022TheranosticsFree full text
  341. Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study.2022Ultrasound in medicine & biology
  342. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics.2022Ultrasound in medicine & biology
  343. An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study.2022World journal of surgical oncologyFree full text
  344. Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.2022World journal of surgical oncologyFree full text
  345. Comparative study of evaluating the microcirculatory function status of primary small HCC between the CE (DCE-MRI) and Non-CE (IVIM-DWI) MR Perfusion Imaging.2021Abdominal radiology (New York)
  346. Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation.2021Abdominal radiology (New York)
  347. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.2021Academic radiology
  348. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.2021AgingFree full text
  349. Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients.2021BMC cancerFree full text
  350. METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC.2021Biochemical and biophysical research communications
  351. The diagnostic value of plasma exosomal hsa_circ_0070396 for hepatocellular carcinoma.2021Biomarkers in medicine
  352. Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma.2021Biosensors & bioelectronics
  353. Differences between exhausted CD8+ T cells in hepatocellular carcinoma patients with and without uremia.2021Canadian journal of physiology and pharmacology
  354. Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma.2021Cancer biomarkers : section A of Disease markersFree full text
  355. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.2021Cancer immunology, immunotherapy : CIIFree full text
  356. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma.2021Cancer letters
  357. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.2021Cancer medicineFree full text
  358. CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression.2021Carcinogenesis
  359. Embolization of the Transhepatic Tract after Percutaneous Portal Vein Interventions: Single-Centre Retrospective Study Comparing n-butyl Cyanoacrylate Versus Coils.2021Cardiovascular and interventional radiology
  360. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma.2021Cell
  361. Cancer-associated fibroblast-derived CXCL11 modulates hepatocellular carcinoma cell migration and tumor metastasis through the circUBAP2/miR-4756/IFIT1/3 axis.2021Cell death & diseaseFree full text
  362. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma.2021CellsFree full text
  363. DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury.2021Cellular & molecular immunologyFree full text
  364. LINC01133 promotes hepatocellular carcinoma progression by sponging miR-199a-5p and activating annexin A2.2021Clinical and translational medicineFree full text
  365. Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B-related hepatocellular carcinoma.2021Clinical and translational medicineFree full text
  366. AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation.2021Clinical and translational medicineFree full text
  367. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.2021Clinical and translational medicineFree full text
  368. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis.2021Clinical hemorheology and microcirculation
  369. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound.2021Clinical hemorheology and microcirculation
  370. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma.2021Clinical hemorheology and microcirculation
  371. Imaging findings of fibrolamellar hepatocellular carcinomas on ultrasonography: A comparison with conventional hepatocellular carcinomas.2021Clinical hemorheology and microcirculation
  372. Current Opinion about Hepatocellular Carcinoma <10 mm.2021Digestion
  373. The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation.2021Disease markersFree full text
  374. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.2021European journal of cancer (Oxford, England : 1990)
  375. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma.2021European journal of radiology
  376. Feasibility of compressed sensing technique for isotropic dynamic contrast-enhanced liver magnetic resonance imaging.2021European journal of radiology
  377. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  378. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm.2021European radiologyFree full text
  379. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.2021Frontiers in immunologyFree full text
  380. AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo.2021Gene therapyFree full text
  381. The mRNA-miRNA-lncRNA Regulatory Network and Factors Associated with Prognosis Prediction of Hepatocellular Carcinoma.2021Genomics, proteomics & bioinformaticsFree full text
  382. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.2021Gut
  383. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?2021Hepatobiliary & pancreatic diseases international : HBPD INT
  384. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.2021Immunotherapy
  385. Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  386. Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.2021Journal for immunotherapy of cancerFree full text
  387. Comparing the efficacy and safety of local-regional treatments for hepatocellular carcinoma with portal/hepatic vein tumor thrombosis in China: a network meta-analysis of randomized controlled trials.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  388. Which is the best combination of surgery for hepatocellular carcinoma with hepatic/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  389. Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters.2021Journal of cancer research and clinical oncologyFree full text
  390. Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2-dependent silencing of SLC7A11.2021Journal of cellular and molecular medicineFree full text
  391. Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.2021Journal of cellular and molecular medicineFree full text
  392. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.2021Journal of experimental & clinical cancer research : CRFree full text
  393. A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  394. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.2021Journal of hematology & oncologyFree full text
  395. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism.2021Journal of hematology & oncologyFree full text
  396. Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages.2021Journal of translational medicineFree full text
  397. The Diagnostic Performance of lncRNAs from Blood Specimens in Patients with Hepatocellular Carcinoma: A Meta-Analysis.2021Laboratory medicine
  398. MNS1 promotes hepatocarcinogenesis and metastasis via activating PI3K/AKT by translocating β-catenin and predicts poor prognosis.2021Liver international : official journal of the International Association for the Study of the Liver
  399. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation.2021Liver international : official journal of the International Association for the Study of the Liver
  400. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.2021Molecular cancerFree full text
  401. Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study.2021Molecular oncologyFree full text
  402. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.2021Nature communicationsFree full text
  403. Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach.2021Surgical endoscopy
  404. Matrix stiffness-mediated effects on macrophages polarization and their LOXL2 expression.2021The FEBS journal
  405. The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.2021The International journal of biological markers
  406. Rare submandibular gland metastasis of hepatocellular carcinoma: case report and review of the literature.2021The Journal of international medical researchFree full text
  407. Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply.2021The Lancet. Oncology
  408. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.2021The Lancet. OncologyRCT
Chinese-language papers (not in the count)3
  1. [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Advances in imaging diagnosis of mixed-type liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  3. [Study of magnetic resonance imaging based on liver imaging reporting and data system for evaluating phosphatidylinositol proteoglycan-3 expression in hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status155
  1. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Lead sponsorStart 2026-07
  2. Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical StudyRecruitingNCT06794073Lead sponsorN/AStart 2026-01
  3. NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingNCT07919717Lead sponsorPhase 2Start 2026-11
  4. A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular CancerNot yet recruitingNCT06935175Lead sponsorPhase 2Start 2025-05
  5. Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)RecruitingNCT06796803Lead sponsorPhase 2/Phase 3Start 2025-02
  6. Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCCRecruitingNCT06537908Lead sponsorStart 2024-08
  7. Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion TherapyRecruitingNCT06382103Lead sponsorStart 2024-05
  8. Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 TherapyRecruitingNCT06870942Lead sponsorPhase 2Start 2022-07
  9. IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular CarcinomaActive, not recruitingNCT06757881Lead sponsorPhase 1Start 2025-01
  10. Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCCStatus unknownNCT06639971Lead sponsorStart 2024-11
  11. Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCCWithdrawnNCT06361758Lead sponsorPhase 2Start 2024-05
  12. Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular CarcinomaStatus unknownNCT06530784Lead sponsorPhase 2Start 2024-07
  13. Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsStatus unknownNCT06031480Lead sponsorPhase 2Start 2023-10
  14. Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With SurgeryStatus unknownNCT05970159Lead sponsorStart 2023-08
  15. Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC PatientsCompletedNCT07321613Lead sponsorStart 2023-05
  16. Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT05701553Lead sponsorStart 2023-01
  17. Study on Screening, Verification and Intervention of High-risk Patients With Liver CancerStatus unknownNCT05721300Lead sponsorN/AStart 2023-02
  18. M-TACE Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05875558Lead sponsorN/AStart 2022-07
  19. A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCCStatus unknownNCT05205629Lead sponsorStart 2022-01
  20. A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical PracticeStatus unknownNCT05200221Lead sponsorStart 2022-01
  21. Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaStatus unknownNCT05389527Lead sponsorPhase 2Start 2022-09
  22. A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCCCompletedNCT05262959Lead sponsorPhase 2Start 2021-12
  23. Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular CarcinomaStatus unknownNCT05087459Lead sponsorStart 2021-06
  24. Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTStatus unknownNCT04850157Lead sponsorPhase 2Start 2021-04
  25. Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Lead sponsorPhase 2/Phase 3Start 2021-03
  26. Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCStatus unknownNCT05056337Lead sponsorPhase 3Start 2021-08
  27. Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCCStatus unknownNCT04943679Lead sponsorStart 2021-06
  28. TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Lead sponsorPhase 2Start 2020-03
  29. Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Lead sponsorPhase 2Start 2020-01
  30. Study of TACE Combined With Camrelizumab in the Treatment of HCC PatientsStatus unknownNCT04483284Lead sponsorPhase 2Start 2020-06
  31. Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.Status unknownNCT04220944Lead sponsorPhase 1Start 2020-01
  32. Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCCStatus unknownNCT04639284Lead sponsorStart 2020-12
  33. A Survey for Factors That Influence Postoperative Treatment Decision-making for Hepatocellular CarcinomaStatus unknownNCT04239781Lead sponsorStart 2020-01
  34. Establishment of Molecular Classification Models for Early Diagnosis of Digestive System CancersCompletedNCT05431621Lead sponsorStart 2020-11
  35. A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor ThrombiStatus unknownNCT03939845Lead sponsorPhase 3Start 2019-04
  36. Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Lead sponsorPhase 2Start 2019-12
  37. Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04926532Lead sponsorPhase 1/Phase 2Start 2019-08
  38. Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular CarcinomaStatus unknownNCT03857815Lead sponsorPhase 2Start 2019-03
  39. Study of Anlotinib After Lenvatinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04080154Lead sponsorPhase 2Start 2019-09
  40. SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular CarcinomaStatus unknownNCT04014101Lead sponsorPhase 2Start 2019-06
  41. Safety and Efficacy of PD-1 Inhibitors in Patients With Liver TransplantStatus unknownNCT03966209Lead sponsorPhase 1Start 2019-05
  42. A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular CarcinomaStatus unknownNCT03416803Lead sponsorN/AStart 2018-02
  43. Adjuvant Therapy With Anlotinib for HCCWithdrawnNCT04947371Lead sponsorPhase 2Start 2018-12
  44. Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine TestStatus unknownNCT03493763Lead sponsorStart 2018-03
  45. SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Lead sponsorN/AStart 2018-12
  46. Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical ResectionStatus unknownNCT03261791Lead sponsorPhase 2Start 2017-07
  47. Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor ThrombusStatus unknownNCT02971345Lead sponsorPhase 3Start 2017-01
  48. A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCCStatus unknownNCT03116984Lead sponsorPhase 3Start 2017-01
  49. Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver CancerStatus unknownNCT02644603Lead sponsorN/AStart 2016-02
  50. TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular CarcinomaStatus unknownNCT02630108Lead sponsorPhase 3Start 2015-12
  51. Combination Treatment for Advanced Liver CancerWithdrawnNCT02149771Lead sponsorPhase 3Start 2014-05
  52. Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular CarcinomaRecruitingNCT07536789Lead (inferred)Phase 2Start 2026-04
  53. A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular CarcinomaRecruitingNCT07328009Lead (inferred)Phase 2Start 2026-01
  54. TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune MicroenvironmentRecruitingNCT07100405Lead (inferred)Start 2025-08
  55. Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingNCT07227012Lead (inferred)Phase 1/Phase 2Start 2025-12
  56. HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)RecruitingNCT06860490Lead (inferred)Phase 2Start 2025-03
  57. Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07047586Lead (inferred)Phase 2Start 2025-07
  58. Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07100392Lead (inferred)Phase 2Start 2025-08
  59. Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentRecruitingNCT07147101Lead (inferred)Start 2025-09
  60. Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic TherapyStatus unknownNCT04994236Lead (inferred)Phase 2Start 2021-07
  61. cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven CriteriaCompletedNCT04842565Lead (inferred)Phase 2Start 2021-05
  62. Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACEStatus unknownNCT03642561Lead (inferred)Phase 2/Phase 3Start 2019-09
  63. Efficacy Study of TACE to Treat Hepatocellular Carcinoma After OperationStatus unknownNCT02631499Lead (inferred)Phase 4Start 2015-12
  64. Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ResectionStatus unknownNCT02281266Lead (inferred)Phase 4Start 2015-01
  65. Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 ExpressionStatus unknownNCT01681446Lead (inferred)Phase 3Start 2012-08
  66. TACE as an Adjuvant Therapy After Hepatectomy for HCCStatus unknownNCT01966133Lead (inferred)Phase 3Start 2011-08
  67. Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) TherapyStatus unknownNCT01102335Lead (inferred)Phase 4Start 2010-04
  68. Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan CriteriaStatus unknownNCT00554125Lead (inferred)Phase 3Start 2007-08
  69. Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular CarcinomaStatus unknownNCT00460681Lead (inferred)Phase 3Start 2007-02
  70. Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative ResectionStatus unknownNCT00561522Lead (inferred)Phase 2/Phase 3Start 2007-11
  71. Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver MetastasesStatus unknownNCT01677728Lead (inferred)Start 2007-01
  72. Safety and Efficacy of Doxorubicin Adsorbed to Magnetic BeadsStatus unknownNCT00054951Lead (inferred)Phase 1/Phase 2Start 2001-06
  73. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  74. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  75. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  76. A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07682272Study sitePhase 2Start 2026-07
  77. A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingNCT07490262Study sitePhase 2/Phase 3Start 2026-03
  78. A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT07392866Study sitePhase 2/Phase 3Start 2026-03
  79. JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingNCT07823348Study sitePhase 3Start 2026-10
  80. Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIsNot yet recruitingNCT07861425Study sitePhase 1Start 2026-11
  81. A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCRecruitingNCT07521852Study sitePhase 2Start 2026-03
  82. A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Study sitePhase 3Start 2026-11
  83. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)RecruitingNCT06858813Study sitePhase 1Start 2025-04
  84. A Phase 2 Study of BB102 in Patients With Hepatocellular CarcinomaNot yet recruitingNCT07239986Study sitePhase 2Start 2025-12
  85. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  86. 29-Gene Liver Cancer Subtype and Immunotherapy EffectivenessNot yet recruitingNCT07100236Study siteStart 2025-08
  87. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  88. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  89. A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Study sitePhase 2Start 2025-06
  90. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  91. HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid TumorsRecruitingNCT06515314Study sitePhase 1Start 2024-10
  92. A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.RecruitingNCT06349980Study sitePhase 2Start 2024-08
  93. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  94. A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative ResectionRecruitingNCT05489289Study sitePhase 3Start 2023-01
  95. A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT05976568Study sitePhase 2/Phase 3Start 2023-09
  96. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCRecruitingNCT05652920Study sitePhase 1/Phase 2Start 2022-12
  97. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  98. Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical TrialActive, not recruitingNCT06842563Study siteStart 2025-02
  99. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  100. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  101. A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06590246Study sitePhase 1/Phase 2Start 2024-09
  102. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Study siteStart 2024-07
  103. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT06310590Study sitePhase 1Start 2023-08
  104. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  105. Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular CarcinomaStatus unknownNCT06178809Study siteStart 2023-12
  106. BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular CarcinomaStatus unknownNCT06111326Study sitePhase 1/Phase 2Start 2023-10
  107. A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaActive, not recruitingNCT05320692Study sitePhase 3Start 2022-08
  108. A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCWithdrawnNCT04465734Study sitePhase 3Start 2022-11
  109. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationCompletedNCT05367687Study sitePhase 2Start 2022-09
  110. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  111. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  112. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  113. Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCCStatus unknownNCT05339321Study sitePhase 1Start 2021-04
  114. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  115. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  116. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  117. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  118. Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04401813Study sitePhase 1Start 2020-06
  119. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  120. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  121. A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Study sitePhase 2Start 2019-09
  122. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  123. AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03971747Study sitePhase 1Start 2019-08
  124. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  125. Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Study sitePhase 1Start 2019-08
  126. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  127. Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaTerminatedNCT03867370Study sitePhase 1/Phase 2Start 2019-04
  128. Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Study sitePhase 2/Phase 3Start 2019-03
  129. Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT04066660Study siteN/AStart 2019-10
  130. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  131. Study of Chiauranib in Patients With Advanced Hepatocellular CarcinomaCompletedNCT03245190Study sitePhase 1/Phase 2Start 2018-04
  132. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  133. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  134. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  135. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  136. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  137. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  138. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  139. Hepatocellular Carcinoma Registry in Asia: The INSIGHT RegistryCompletedNCT03233360Study siteStart 2017-04
  140. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  141. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  142. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in ChinaStatus unknownNCT02743065Study siteStart 2016-09
  143. Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Study sitePhase 1Start 2016-09
  144. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  145. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  146. Efficacy and Safety Study of TLC388 to Advanced Hepatocellular CarcinomaTerminatedNCT02267213Study sitePhase 2Start 2014-04
  147. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  148. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCStatus unknownNCT02018757Study sitePhase 2Start 2014-01
  149. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03
  150. the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular CarcinomaCompletedNCT01717066Study siteN/AStart 2012-11
  151. Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT01489566Study sitePhase 3Start 2011-07
  152. A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical ResectionTerminatedNCT01402908Study sitePhase 3Start 2011-08
  153. Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Study sitePhase 2Start 2010-12
  154. Urea Cream Treatment Sorafenib-Associated HSFR in HCCCompletedNCT01934829Study sitePhase 2Start 2009-07
  155. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 134 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.4%.

Papers led
134
2021–2025
Trials led
22
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 222220212022: 323220222023: 292920232024: 282820242025: 21212025

17 hospitals in Shanghai for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 20

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07213791

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06468280

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  3. Recruiting
    IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06662110

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  4. Recruiting
    Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
    Phase
    Not given
    Started
    2022-03
    Registry
    NCT05347524

    Age 18 years to 74 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  5. Recruiting
    Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04710758

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  6. Not yet recruiting
    A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07333573

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  7. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07508956

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  8. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07257380

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  9. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  10. Recruiting
    Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07392892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan

  11. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  12. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  13. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  14. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  15. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  16. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  17. Recruiting
    RCT of EFTR Versus STER for GIST Treatment
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07411118

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  18. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  19. Recruiting
    Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05671822

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  20. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyChemotherapy & combined treatmentImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine
Papers it led134
  1. Photo-triggered engineered microbes achieving dual epigenetic immunomodulation for gastric cancer.2026Biomaterials
  2. Feasibility and Safety of Endoscopic Full-Thickness Resection for Gastric Submucosal Tumors With Extraluminal Growth.2026Journal of gastroenterology and hepatology
  3. Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase2025BMC cancerFree full text
  4. Premature death patterns and trends of stomach cancer in Pudong, Shanghai: a population based study.2025BMC cancerFree full text
  5. Phosphorylation of MSX1 controls tumorigenesis and bone development through targeting FBXW7 degradation.2025Cancer letters
  6. TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages.2025Cell death & diseaseFree full text
  7. Oxidative stress and Kras mutation in Mist1+ cells act in a double-hit manner to drive gastric tumorigenesis.2025Cell reports
  8. Cancer-associated fibroblast miR-148a-5p/CALD1/collagen VI pathway promotes proliferation in Helicobacter pylori-positive gastric cancer.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  9. 18 F-FDG Versus 68 Ga-FAPI PET/MRI Findings in a Case of Primary Gastric Melanoma.2025Clinical nuclear medicine
  10. Efficacy and safety of endoscopic intraperitoneal subserosal dissection for gastric submucosal tumors with extraluminal growth pattern.2025EndoscopyFree full text
  11. EPDR1 promotes gastric cancer progression via STAT3-mediated fatty acid metabolic reprogramming.2025European journal of medical researchFree full text
  12. Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer.2025European radiology
  13. m6A transferase KIAA1429 mediates the upregulation of LncRNA LINC00968 promoting the progression of gastric cancer cells.2025HereditasFree full text
  14. T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer.2025Immunologic research
  15. SYT4 Interacts with PSMC6 to Facilitate Malignant Progression in Gastric Carcinoma via Activating Wnt/β-catenin Signaling.2025International journal of biological sciencesFree full text
  16. Mechanistic insights into PD-1 inhibitor-associated immune thrombocytopenia: a case report integrating longitudinal transcriptomic profiling.2025Journal for immunotherapy of cancerFree full text
  17. Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer.2025Journal for immunotherapy of cancerFree full text
  18. Nutritional support after hospital discharge reduces long-term mortality in patients after gastric cancer surgery: Secondary analysis of a prospective randomized trial.2025Nutrition (Burbank, Los Angeles County, Calif.)RCT
  19. Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer.2025Signal transduction and targeted therapyFree full text
  20. Efficacy and safety of endoscopic submucosal dissection for pyloric neoplasms.2025Surgical endoscopy
  21. Feasibility and safety of endoscopic resection for cardial submucosal tumors more than 30 mm in diameter.2025Surgical endoscopy
  22. Zipper endoscopic full-thickness resection: a pilot study in subepithelial tumor management (with video).2025Surgical endoscopy
  23. Multi-omics integration reveals gut Microbiome and Short-chain fatty acid profiles in gastric cancer cachexia patients and their clinical significance.2025World journal of microbiology & biotechnology
  24. High-Throughput Metabolic Pattern Screening Strategy for Early Colorectal and Gastric Cancers Based on Covalent Organic Frameworks-Assisted Laser Desorption/Ionization Mass Spectrometry.2024Analytical chemistry
  25. An experience of laparoscopic-assisted D2 radical gastrectomy with uncut Roux-en-Y anastomosis for distal gastric cancer.2024Asian journal of surgery
  26. Modeling human gastric cancers in immunocompetent mice.2024Cancer biology & medicineFree full text
  27. Road of no return - loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer.2024Cancer biology & medicineFree full text
  28. Transarterial Infusion Chemotherapy and Embolization for Patients With Unresectable Advanced Cancer of Stomach or Gastroesophageal Junction: A Retrospective Study.2024Cancer medicineFree full text
  29. Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study.2024Cancer medicineFree full text
  30. IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages.2024Cell death & diseaseFree full text
  31. Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  32. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.2024Clinical and translational medicineFree full text
  33. Elevated 18F-FDG uptake in subcutaneous adipose tissue correlates negatively with nutritional status and prognostic survival in cachexia patients with gastric cancer.2024Clinical nutrition (Edinburgh, Scotland)
  34. REST Promotes Autophagy in Gastric Cancer by Transcriptionally Activating FABP6 to Inhibit the Akt/mTOR Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  35. Amlodipine inhibits Synaptotagmin-4's oncogenic activity on gastric cancer proliferation by targeting calcium signaling.2024Functional & integrative genomicsFree full text
  36. Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images.2024Gastrointestinal endoscopy
  37. New endoscopic closure technique, "internal traction-assisted suspended closure," for GI defect closure: a pilot study (with video).2024Gastrointestinal endoscopy
  38. IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.2024Journal of cancer research and clinical oncologyFree full text
  39. A scoring system to predict the technical difficulty of endoscopic resection for cardial submucosal tumors.2024Journal of gastroenterology and hepatology
  40. Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report.2024Journal of immunotherapy (Hagerstown, Md. : 1997)Free full text
  41. Circular RNA LDLRAD3 promotes gastric cancer progression by upregulating COL4A5 through sponging miR-h37.2024Journal of the Chinese Medical Association : JCMAFree full text
  42. DeepRisk network: an AI-based tool for digital pathology signature and treatment responsiveness of gastric cancer using whole-slide images.2024Journal of translational medicineFree full text
  43. Epstein-Barr virus infection upregulates extracellular OLFM4 to activate YAP signaling during gastric cancer progression.2024Nature communicationsFree full text
  44. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.2024Nature communicationsFree full text
  45. Early intravenous branched-chain amino acid-enriched nutrition supplementation in older patients undergoing gastric surgery: a randomized clinical trial.2024Nutrition journalRCTFree full text
  46. ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases.2024Oncogene
  47. Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study.2024Surgical endoscopy
  48. A cofactor-induced repressive type of transcription factor condensation can be induced by synthetic peptides to suppress tumorigenesis.2024The EMBO journalFree full text
  49. Reactivating Hippo by drug compounds to suppress gastric cancer and enhance chemotherapy sensitivity.2024The Journal of biological chemistryFree full text
  50. The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to promote YAP signaling in gastric cancer.2024The Journal of clinical investigationFree full text
  51. Endoscopic features and treatments of gastric cystica profunda.2024World journal of gastroenterologyFree full text
  52. Prognostic value of preoperative CT features for disease-free survival in patients with primary gastric gastrointestinal stromal tumors after resection.2023Abdominal radiology (New York)
  53. The largest lymph node defined response to neoadjuvant chemotherapy can predict long-term prognosis in locally advanced gastric cancer.2023Abdominal radiology (New York)
  54. JUNB mediates oxaliplatin resistance via the MAPK signaling pathway in gastric cancer by chromatin accessibility and transcriptomic analysis.2023Acta biochimica et biophysica SinicaFree full text
  55. The Hippo signaling pathway in gastric cancer.2023Acta biochimica et biophysica SinicaFree full text
  56. ASO Author Reflections: The Prognostic Value of Pathologic Complete Response After Neoadjuvant Chemotherapy in Gastric Cancer.2023Annals of surgical oncology
  57. Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China.2023Annals of surgical oncology
  58. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA).2023BMC cancerFree full text
  59. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.2023Cancer immunology, immunotherapy : CIIFree full text
  60. Identifying HER2 from serum-derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab-based therapy.2023Cancer medicineFree full text
  61. Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).2023Cancer medicineFree full text
  62. Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer.2023Cell reports. MedicineFree full text
  63. Single-cell RNA sequencing reveals the lineage of malignant epithelial cells and upregulation of TAGLN2 promotes peritoneal metastasis in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  64. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  65. Endoscopic full-thickness resection, indication, methods and perspectives.2023Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  66. Endoscopic removal of an extraluminal gastrointestinal stromal tumor recurrence located on the surgical stapler line at gastroesophageal junction.2023EndoscopyFree full text
  67. Immune landscape and prognostic gene signatures in gastric cancer: implications for cachexia and clinical outcomes.2023Frontiers in immunologyFree full text
  68. Submucosal Tunneling Techniques for Tumor Resection.2023Gastrointestinal endoscopy clinics of North America
  69. CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.2023International journal of biological sciencesFree full text
  70. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.2023International journal of cancerRCTFree full text
  71. Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: a retrospective cohort study.2023International journal of surgery (London, England)Free full text
  72. Intraoperative Pathological Evaluation of Suspicious Peritoneal Nodules for Surgical Decision-making in Gastric Cancer.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  73. 124I-Labeled Immuno-PET Targeting hTREM2 for the Diagnosis of Gastric Carcinoma.2023Molecular pharmaceutics
  74. Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer.2023Nature communicationsFree full text
  75. A YAP/TAZ-CD54 axis is required for CXCR2-CD44- tumor-specific neutrophils to suppress gastric cancer.2023Protein & cellFree full text
  76. Risk factors for complications and incomplete resection after endoscopic resection for duodenal submucosal tumors.2023Surgical endoscopy
  77. Endoscopic resection and suturing methods for non-ampullary duodenal submucosal tumors: "mini-invasive" treatments that should never be underestimated.2023Surgical endoscopy
  78. Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China.2023Surgical endoscopy
  79. COLEC12 Promotes Tumor Progression and Is Correlated With Poor Prognosis in Gastric Cancer.2023Technology in cancer research & treatmentFree full text
  80. Diagnostic and economic value of carcinoembryonic antigen, carbohydrate antigen 19-9, and carbohydrate antigen 72-4 in gastrointestinal cancers.2023World journal of gastroenterologyFree full text
  81. Exosome Metabolic Patterns on Aptamer-Coupled Polymorphic Carbon for Precise Detection of Early Gastric Cancer.2022ACS nano
  82. Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness.2022Annals of surgery
  83. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.2022BMC cancerFree full text
  84. Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.2022BMC gastroenterologyFree full text
  85. Identification of metabolism-related genes for predicting peritoneal metastasis in patients with gastric cancer.2022BMC genomic dataFree full text
  86. TIM3+ cells in gastric cancer: clinical correlates and association with immune context.2022British journal of cancerFree full text
  87. Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer.2022British journal of cancerFree full text
  88. Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis.2022British journal of cancerFree full text
  89. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.2022Cancer scienceFree full text
  90. Reticulon 2 promotes gastric cancer metastasis via activating endoplasmic reticulum Ca2+ efflux-mediated ERK signalling.2022Cell death & diseaseFree full text
  91. Ubiquitylation of cyclin C by HACE1 regulates cisplatin-associated sensitivity in gastric cancer.2022Clinical and translational medicineFree full text
  92. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China.2022Diagnostic pathologyFree full text
  93. Endoscopic intraperitoneal subserosal dissection combined with endoscopic ultrasonography-assisted location of an extraluminally growing stromal tumor.2022Endoscopy
  94. Management of an esophagopleural fistula after resection of giant submucosal tumor of the cardia.2022EndoscopyFree full text
  95. circBGN accelerates gastric cancer cell proliferation and invasion via activating IL6/STAT3 signaling pathway.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  96. RNA m5C regulator-mediated modification patterns and the cross-talk between tumor microenvironment infiltration in gastric cancer.2022Frontiers in immunologyFree full text
  97. Automatic captioning of early gastric cancer using magnification endoscopy with narrow-band imaging.2022Gastrointestinal endoscopy
  98. Endoscopic resection of upper GI extraluminal tumors (with videos).2022Gastrointestinal endoscopy
  99. Endoscopic submucosal dissection for gastric adenocarcinoma of the fundic gland type (chief cell predominate type): Four years' experience from a tertiary hospital.2022Journal of digestive diseases
  100. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.2022Journal of experimental & clinical cancer research : CRFree full text
  101. Predictors of the difficulty for endoscopic resection of gastric gastrointestinal stromal tumor and follow-up data.2022Journal of gastroenterology and hepatology
  102. Comparison of safety and short-term outcomes between endoscopic and laparoscopic resections of gastric gastrointestinal stromal tumors with a diameter of 2-5 cm.2022Journal of gastroenterology and hepatology
  103. IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer.2022Journal of translational medicineFree full text
  104. EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal.2022Molecular cancer research : MCRFree full text
  105. Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with 89Zr-Labeled Anti-CD11b Positron Emission Tomography Imaging.2022Molecular pharmaceutics
  106. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.2022Nature communicationsFree full text
  107. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies.2022Nature communicationsFree full text
  108. Clinicopathologic features of gastric glomus tumor: A report of 15 cases and literature review.2022Pathology oncology research : PORFree full text
  109. Synchronous three different types of stomach tumors on 18F-FDG PET/CT.2022Revista espanola de medicina nuclear e imagen molecular
  110. Landscape of esophageal submucosal tunneling endoscopic resection-related adverse events in a standardized lexicon: a large volume of 1701 cases.2022Surgical endoscopy
  111. Long-term prognosis of small gastric gastrointestinal stromal tumors with high histological grade: a longitudinal nested cohort study.2022Surgical endoscopy
  112. SP70 is a potential biomarker to identify gastric fundic gland neoplasms.2022World journal of surgical oncologyFree full text
  113. ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer.2021Annals of surgical oncology
  114. Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.2021Annals of surgical oncology
  115. Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer.2021BMC cancerFree full text
  116. G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer.2021British journal of cancerFree full text
  117. Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes.2021Clinical and experimental medicine
  118. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia.2021Clinical nutrition (Edinburgh, Scotland)
  119. Reply letter to the editor-post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial.2021Clinical nutrition (Edinburgh, Scotland)
  120. Post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial.2021Clinical nutrition (Edinburgh, Scotland)RCT
  121. BOP1 Silencing Suppresses Gastric Cancer Proliferation through p53 Modulation.2021Current medical science
  122. Utility of preoperative computed tomography features in predicting the Ki-67 labeling index of gastric gastrointestinal stromal tumors.2021European journal of radiology
  123. Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers.2021Experimental cell research
  124. Identifying early gastric cancer under magnifying narrow-band images with deep learning: a multicenter study.2021Gastrointestinal endoscopy
  125. Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.2021GutFree full text
  126. Submucosal tunneling endoscopic resection treatment of multiple gastrointestinal submucosal tumors.2021Journal of gastroenterology and hepatology
  127. High Expression of TRIM15 Is Associated with Tumor Invasion and Predicts Poor Prognosis in Patients with Gastric Cancer.2021Journal of investigative surgery : the official journal of the Academy of Surgical Research
  128. Reevaluation of lymphovascular invasion in gastric cancer using endothelial markers D2-40 and EVG: Enhanced detection, better predictor of lymph node metastasis and biological aggressiveness.2021Journal of surgical oncology
  129. Magnetic porous carbon-dependent platform for the determination of N-glycans from urine exosomes.2021Mikrochimica acta
  130. Demethylation of the SFRP4 Promoter Drives Gastric Cancer Progression via the Wnt Pathway.2021Molecular cancer research : MCR
  131. HER2 promotes epithelial-mesenchymal transition through regulating osteopontin in gastric cancer.2021Pathology, research and practice
  132. Improved submucosal tunneling endoscopic resection with slant tunnel for submucosal tumors in proximal esophagus.2021Surgical endoscopy
  133. Controlled hypertension under hemostasis prevents post-gastric endoscopic submucosal dissection bleeding: a prospective randomized controlled trial.2021Surgical endoscopyRCT
  134. A novel nomogram based on cardia invasion and chemotherapy to predict postoperative overall survival of gastric cancer patients.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)17
  1. [Clinicopathological characteristics and prognostic factors in 36 cases of early-stage gastric mixed adenoneuroendocrine carcinoma].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Clinical study on endoscopic resection of giant submucosal tumors in the esophagus or gastric cardia].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Analysis of risk factors for lymph node metastasis in 1096 patients with early gastric cancer and establishment of a predictive nomogram].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Clinicopathological features and prognosis of early-onset gastric cancer: a large-scale retrospective real-world study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Trends, challenges, and reflections on early-onset gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Progress in the application of laparoscopic and endoscopic cooperative surgery in gastrointestinal stromal tumors].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Clinicopathological and molecular diagnostic features of early-onset gastric cancer: a study based on data from a single-center dedicated gastric cancer database].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [A multicenter retrospective study on the efficacy of different anti-reflux reconstruction methods after proximal gastrectomy for gastric cancer].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  10. [Dilemmas in definition and classification of adenocarcinoma of esophagogastric junction: from history to current status].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  11. [Application value and difficulty analysis of fluorescence laparoscopy in lymphadenectomy of gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Advantages and disadvantages of transthoracic approach for adenocarcinoma of the esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Laparoscopic proximal gastrectomy and lymph node resection in adenocarcinoma of the esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
  15. [Clinicopathological features and survival analysis of gastric cancer patients with neuroendocrine differentiation after radical resection].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [Interpretation of key points of Chinese expert consensus on function-preserving gastrectomy for gastric cancer (2021)].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  17. [Research progression in clinical treatment of gastric cancer in 2020].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status70
  1. Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant TreatmentNot yet recruitingNCT07508956Lead sponsorPhase 3Start 2026-06
  2. A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric CancerNot yet recruitingNCT07333573Lead sponsorPhase 1/Phase 2Start 2026-01
  3. Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)Not yet recruitingNCT07257380Lead sponsorPhase 2Start 2025-12
  4. Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric CancerRecruitingNCT06468280Lead sponsorPhase 2Start 2024-11
  5. IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric CancerRecruitingNCT06662110Lead sponsorStart 2024-08
  6. Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective StudyRecruitingNCT05347524Lead sponsorStart 2022-03
  7. Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric CancerRecruitingNCT04710758Lead sponsorN/AStart 2021-01
  8. Neoadjuvant TACiE in Locally Advanced Gastric CancerStatus unknownNCT05346874Lead sponsorPhase 2Start 2022-06
  9. A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach AdenocarcinomaStatus unknownNCT04799548Lead sponsorPhase 2Start 2021-12
  10. AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-GastricStatus unknownNCT05224596Lead sponsorStart 2021-01
  11. Establishment of Molecular Classification Models for Early Diagnosis of Digestive System CancersCompletedNCT05431621Lead sponsorStart 2020-11
  12. Potential Clinical Utilities of Circulating Tumor DNA in Gastric CancerStatus unknownNCT04000425Lead sponsorStart 2018-12
  13. Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. ChemoradiotherapyStatus unknownNCT03680261Lead sponsorPhase 3Start 2018-10
  14. Study On Safety Of Laparoscopic Total Gastrectomy For Clinical Stage I Gastric CancerCompletedNCT03007550Lead sponsorN/AStart 2017-01
  15. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Lead sponsorStart 2017-12
  16. Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric CancerStatus unknownNCT03229096Lead sponsorPhase 2Start 2017-02
  17. To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.Status unknownNCT03001726Lead sponsorStart 2017-01
  18. A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric CancerStatus unknownNCT02409199Lead sponsorPhase 2/Phase 3Start 2015-06
  19. Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin BlocksStatus unknownNCT02852096Lead sponsorN/AStart 2015-11
  20. Trastuzumab Based Therapy in HER2 Positive AGCCompletedNCT03024450Lead sponsorStart 2012-01
  21. Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node MetastasisCompletedNCT02071043Lead sponsorPhase 2Start 2008-11
  22. A Study of LY4337713 in Participants With FAP-Positive Solid TumorsRecruitingNCT07213791Lead (inferred)Phase 1Start 2025-10
  23. Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingNCT07392892Study sitePhase 2/Phase 3Start 2026-05
  24. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  25. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Study sitePhase 3Start 2026-09
  26. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  27. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  28. RCT of EFTR Versus STER for GIST TreatmentRecruitingNCT07411118Study siteN/AStart 2025-02
  29. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  30. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Study sitePhase 3Start 2025-08
  31. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  32. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  33. Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric CancerRecruitingNCT05671822Study sitePhase 2Start 2023-03
  34. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  35. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  36. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  37. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  38. Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1CompletedNCT05383482Study sitePhase 1/Phase 2Start 2022-07
  39. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  40. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  41. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  42. Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric CancerStatus unknownNCT05203549Study siteStart 2021-05
  43. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  44. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  45. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  46. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  47. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  48. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  49. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  50. A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid TumorsStatus unknownNCT04511871Study sitePhase 1Start 2020-07
  51. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  52. A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid TumorsTerminatedNCT03960060Study sitePhase 1Start 2019-05
  53. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  54. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  55. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  56. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  57. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  58. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  59. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  60. Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid TumorsCompletedNCT03175497Study sitePhase 1Start 2017-07
  61. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  62. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  63. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  64. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  65. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  66. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  67. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  68. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  69. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09
  70. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 3 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

8 hospitals in Shanghai for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

14 hospitals in Shanghai for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 5 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 3320242025: 002025

45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 28 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 5.3%.

Papers led
28
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 6620232024: 5520242025: 662025

21 hospitals in Shanghai for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    RCT of EFTR Versus STER for GIST Treatment
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07411118

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led28
  1. The value of a nomogram model based on CT imaging features in differentiating duodenal gastrointestinal stromal tumors from pancreatic head neuroendocrine tumors.2025Abdominal radiology (New York)
  2. Endoscopic resection for small rectal gastrointestinal stromal tumors: a pilot study.2025BMC gastroenterology
  3. A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration.2025Diagnostic pathology
  4. Hidden risk factors for recurrence of jejunoileal Gastrointestinal stromal tumors with low NIH classification: implications for surveillance and adjuvant therapy.2025Journal of translational medicine
  5. RNA profiling and immunohistochemistry analyses of circRNAs in imatinib-resistant gastrointestinal stromal tumors.2025Journal of translational medicine
  6. Endoscopic treatment outcome of oesophageal gastrointestinal stromal tumours.2025World journal of gastroenterology
  7. Safety, effectiveness and the optimal duration of preoperative imatinib in locally advanced gastric gastrointestinal stromal tumors: A retrospective cohort study.2024Cancer medicineFree full text
  8. A case report of abdominal metastatic dermatofibrosarcoma protuberans misdiagnosed as gastrointestinal stromal tumor.2024Diagnostic pathology
  9. Proteomic Characterization Identifies Clinically Relevant Subgroups of Gastrointestinal Stromal Tumors.2024Gastroenterology
  10. Automatically optimized radiomics modeling system for small gastric submucosal tumor (<2 cm) discrimination based on EUS images.2024Gastrointestinal endoscopy
  11. Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study.2024Surgical endoscopy
  12. Prognostic value of preoperative CT features for disease-free survival in patients with primary gastric gastrointestinal stromal tumors after resection.2023Abdominal radiology (New York)
  13. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination.2023Cell death & disease
  14. Endoscopic removal of an extraluminal gastrointestinal stromal tumor recurrence located on the surgical stapler line at gastroesophageal junction.2023EndoscopyFree full text
  15. New insight on the correlation of immune landscapes with immune markers expression in different risk classification of gastrointestinal stromal tumors.2023Journal of gastroenterology
  16. Endoscopic resection and suturing methods for non-ampullary duodenal submucosal tumors: "mini-invasive" treatments that should never be underestimated.2023Surgical endoscopy
  17. Clinical outcomes of endoscopic resection for the treatment of esophageal gastrointestinal stromal tumors: a ten-year experience from a large tertiary center in China.2023Surgical endoscopy
  18. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.2022Cell communication and signaling : CCS
  19. Endoscopic intraperitoneal subserosal dissection combined with endoscopic ultrasonography-assisted location of an extraluminally growing stromal tumor.2022Endoscopy
  20. Comparison of safety and short-term outcomes between endoscopic and laparoscopic resections of gastric gastrointestinal stromal tumors with a diameter of 2-5 cm.2022Journal of gastroenterology and hepatology
  21. Predictors of the difficulty for endoscopic resection of gastric gastrointestinal stromal tumor and follow-up data.2022Journal of gastroenterology and hepatology
  22. A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type gastrointestinal stromal tumor.2022Molecular genetics & genomic medicine
  23. Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.2022Pathology, research and practice
  24. Long-term prognosis of small gastric gastrointestinal stromal tumors with high histological grade: a longitudinal nested cohort study.2022Surgical endoscopy
  25. Utility of preoperative computed tomography features in predicting the Ki-67 labeling index of gastric gastrointestinal stromal tumors.2021European journal of radiology
  26. Endoscopic transmural route for dissection of gastric submucosal tumors with extraluminal growth: experience in two cases.2021GutFree full text
  27. Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  28. BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes.2021Oncoimmunology
Chinese-language papers (not in the count)7
  1. [Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Clinicopathological features and prognostic factors of gastric intermediate-risk gastrointestinal stromal tumor after surgical resection: a retrospective study].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Clinical significance of pathological diagnosis and genetic abnormalities detection in gastrointestinal stromal tumor using endoscopic biopsy].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Progress in the application of laparoscopic and endoscopic cooperative surgery in gastrointestinal stromal tumors].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Research status and prospect of immunotherapy in gastrointestinal stromal tumors].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [The feasibility analysis of multi-slice spiral CT features of gastric stromal tumors in predicting pathological National Institutes of Health risk classification].2022Zhonghua yi xue za zhi
  7. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with KIT/PDGFRA gene "homozygous mutation": a multicenter retrospective cohort study].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)23
  1. Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.2020Aging
  2. Upregulation of ZNF148 in SDHB-deficient gastrointestinal stromal tumor potentiates Forkhead box M1-mediated transcription and promotes tumor cell invasion.2020Cancer science
  3. Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: Summary of 14-year clinical experience in a single center.2020International journal of surgery (London, England)
  4. A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors.2020Medical science monitor : international medical journal of experimental and clinical research
  5. Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors.2020Oncoimmunology
  6. Microscopic positive tumor margin does not increase the rate of recurrence in endoscopic resected gastric mesenchymal tumors compared to negative tumor margin.2020Surgical endoscopy
  7. [The shift of the treatment strategy of gastrointestinal stromal tumor from the surgical perspective].2020Zhonghua wai ke za zhi [Chinese journal of surgery]
  8. [Research advance of liquid biopsy in gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Retrospect of 2019: focus on the research progress of gastric neoplasm].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses.2019Journal of cancer research and clinical oncology
  12. Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs).2019Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  13. Endoscopic full-thickness resection (EFTR) without laparoscopic assistance for nonampullary duodenal subepithelial lesions: our clinical experience of 32 cases.2019Surgical endoscopy
  14. Efficacy and safety of endoscopic resection for small submucosal tumors originating from the muscularis propria layer in the gastric fundus.2019Surgical endoscopy
  15. [Research advances in the secondary resistance mechanism of imatinib in gastrointestinal stromal tumors].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. Submucosal tunnel endoscopic resection for extraluminal tumors: a novel endoscopic method for en bloc resection of predominant extraluminal growing subepithelial tumors or extra-gastrointestinal tumors (with videos).2018Gastrointestinal endoscopy
  17. Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.2017Acta biochimica et biophysica Sinica
  18. Long-term Outcomes of Submucosal Tunneling Endoscopic Resection for Upper Gastrointestinal Submucosal Tumors.2017Annals of surgery
  19. A novel grasp-and-loop closure method for defect closure after endoscopic full-thickness resection (with video).2017Surgical endoscopy
  20. Endoscopic Full-thickness Resection (EFTR) for Gastrointestinal Subepithelial Tumors.2016Gastrointestinal endoscopy clinics of North America
  21. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.2016Laboratory investigation; a journal of technical methods and pathology
  22. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.2016Oncotarget
  23. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.2016Scientific reports
All its trials on ClinicalTrials.gov, any status6
  1. Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GISTStatus unknownNCT02353052Lead sponsorStart 2013-07
  2. RCT of EFTR Versus STER for GIST TreatmentRecruitingNCT07411118Study siteN/AStart 2025-02
  3. Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GISTActive, not recruitingNCT07837271Study siteStart 2026-01
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  5. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  6. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

15 hospitals in Shanghai for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 23 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.4%.

Papers led
23
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 121220232024: 5520242025: 442025

15 hospitals in Shanghai for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07638683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT05965115

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  4. Recruiting
    Longitudinal Data Registry of Plasma Cell Dyscrasia
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06760052

    Age 19 years to 99 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  5. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  7. Recruiting
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07623798

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  8. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  9. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  10. Recruiting
    A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06700395

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai

  11. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  12. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  13. Not yet recruiting
    A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06895512

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications
Departments in papersPathology / laboratory medicine
Papers it led23
  1. LRP8-dependent cholesterol metabolism modulates mTORC1 signaling and apoptotic pathways in multiple myeloma.2025Cell death & diseaseFree full text
  2. Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway.2025Cell death & diseaseFree full text
  3. Real-World Data Analysis on Early Mortality in Chinese Multiple Myeloma Patients: Analysis of 1093 Patients During a 15-Year Period.2025Hematological oncology
  4. NR5A2 (located on chromosome 1q32) inhibits ferroptosis and promotes drug resistance by regulating phospholipid remodeling in multiple myeloma.2025International journal of biological sciencesFree full text
  5. Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.2024BMC cancerFree full text
  6. The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis.2024British journal of haematology
  7. Detection of circulating plasma cells in peripheral blood using deep learning-based morphological analysis.2024Cancer
  8. Update on the outcome of M-protein screening program of multiple myeloma in China: A 7-year cohort study.2024Cancer medicineFree full text
  9. IgE-kappa multiple myeloma with kappa free light chain: a case report.2024Scandinavian journal of clinical and laboratory investigation
  10. Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.2023Annals of hematology
  11. PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion.2023British journal of haematology
  12. Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma.2023British journal of haematology
  13. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.2023Cancer
  14. The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.2023Cancer medicineFree full text
  15. The obesity paradox in multiple myeloma: A report from Multiple Myeloma Research Foundation (MMRF) dataset.2023Cancer medicineFree full text
  16. The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center.2023Cancer medicineFree full text
  17. Thrombosis events in Chinese patients with newly diagnosed multiple myeloma.2023Clinical and experimental medicine
  18. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients.2023Clinical and experimental medicine
  19. Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.2023Hematology (Amsterdam, Netherlands)
  20. Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma.2023International journal of molecular sciencesFree full text
  21. A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma.2023International journal of molecular sciencesFree full text
  22. The role of KIAA1191 in the necroptotic pathway of multiple myeloma.2022Annals of hematology
  23. Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.2021Annals of hematology
Chinese-language papers (not in the count)3
  1. [Comparison of criteria for metabolically healthy overweight/obesity in Shanghai Changfeng study].2022Zhonghua nei ke za zhi
  2. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Progress of interleukin-6-related antibodies in the treatment of multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status20
  1. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Lead sponsorStart 2026-06
  2. A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).RecruitingNCT07638683Lead sponsorPhase 2Start 2026-05
  3. Longitudinal Data Registry of Plasma Cell DyscrasiaRecruitingNCT06760052Lead sponsorStart 2023-03
  4. The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE StudyRecruitingNCT05965115Lead sponsorStart 2023-07
  5. Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MMStatus unknownNCT03706547Lead (inferred)Phase 1Start 2018-10
  6. A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Study sitePhase 3Start 2026-06
  7. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  8. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  9. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  10. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  11. A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingNCT06895512Study sitePhase 3Start 2025-04
  12. A Clinical Study of TQB2029 for Injection in Subjects With Multiple MyelomaRecruitingNCT06700395Study sitePhase 1Start 2024-11
  13. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  14. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  15. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03
  16. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  17. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  18. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  19. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  20. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07266051

    Age 18 years to Not stated (registered criteria)

    Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruitingNCT07266051Study siteStart 2025-12
  2. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 002025

4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment & relapse
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

7 hospitals in Shanghai for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    EFG vs IVIG in TAMG
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07231523

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsThymus & thymectomy
Papers it led1
  1. Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial.2025Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
All its trials on ClinicalTrials.gov, any status1
  1. EFG vs IVIG in TAMGNot yet recruitingNCT07231523Lead sponsorPhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 33 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 17.6%.

Papers led
33
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 111120212022: 5520222023: 9920232024: 5520242025: 332025

8 hospitals in Shanghai for Takayasu arteritis100 hospitals in China for Takayasu arteritis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
    Phase
    Phase 4
    Started
    2024-06
    Registry
    NCT06498089

    Age 18 years to 65 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    A Pilot Study in Severe Patients With Takayasu Arteritis.
    Phase
    Phase 4
    Started
    2020-03
    Registry
    NCT04300686

    Age 14 years to 100 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunologyRadiology / nuclear medicine
Papers it led33
  1. 2025 Chinese guideline for the imaging diagnosis and evaluation of Takayasu arteritis.2025Advances in rheumatology (London, England)
  2. A novel ultrasound-based score for assessing carotid artery activity in Takayasu's arteritis.2025Clinical and experimental rheumatology
  3. Association of PET vascular activity score with Takayasu's arteritis angiographic progression.2025European journal of nuclear medicine and molecular imaging
  4. Bibliometric analysis and visualisation of research hotspots and frontiers in Takayasu's arteritis.2024Clinical and experimental rheumatology
  5. Epidemiology of large vasculitis in Shanghai, China: A 10-year multicenter hospital-based study and systematic review.2024International journal of rheumatic diseases
  6. Pro-fibrotic effect of the susceptible gene PCSK5 in vascular fibrosis of Takayasu arteritis via TGF-β and SMAD3 signaling pathway activation.2024Journal of autoimmunity
  7. Comment on: Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis. Reply.2024Rheumatology (Oxford, England)
  8. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.2024Rheumatology (Oxford, England)RCT
  9. High level of serum complement 3 is a risk factor for vascular stenosis progression in TA patients receiving tocilizumab: a prospective observational study.2023Arthritis research & therapy
  10. Exploration of molecular signatures associated with different clinical features of Takayasu arteritis based on a prospective cohort study.2023Clinical immunology (Orlando, Fla.)
  11. Associations of microcirculation damage on nailfold capillaroscopy with supra-aortic severe ischemic events in patients with Takayasu arteritis.2023Clinical rheumatology
  12. An exploration of the feasibility and clinical value of half-dose 5-h total-body 18F-FDG PET/CT scan in patients with Takayasu arteritis.2023European journal of nuclear medicine and molecular imaging
  13. COVID-19 infection characteristics, risk factors and its potential impacts on Takayasu arteritis: a web-based survey in a large cohort.2023Frontiers in immunology
  14. COVID-19 vaccine uptake, hesitancy and clinical effects on patients with Takayasu's arteritis: A web-based questionnaire survey from a large cohort.2023Frontiers in immunology
  15. The role of plateletcrit in Takayasu arteritis: A potential biomarker for disease activity and 6-month treatment response.2023International journal of rheumatic diseases
  16. PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study.2023Rheumatology (Oxford, England)
  17. A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.2023Translational research : the journal of laboratory and clinical medicine
  18. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.2022Annals of the rheumatic diseases
  19. A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis.2022Arthritis research & therapy
  20. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study.2022Seminars in arthritis and rheumatism
  21. Transcatheter Aortic Valve Replacement for Aortic Regurgitation Caused by Takayasu Arteritis.2022The Annals of thoracic surgery
  22. Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis.2022The Journal of rheumatology
  23. Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension.2021Arthritis research & therapy
  24. Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis.2021Arthritis research & therapy
  25. Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts.2021Clinical and experimental rheumatology
  26. The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study.2021Clinical and experimental rheumatology
  27. Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis.2021Clinical rheumatology
  28. Detection of mural inflammation with low b-value diffusion-weighted imaging in patients with active Takayasu Arteritis.2021European radiology
  29. Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis.2021Frontiers in immunology
  30. Epidemiology of Takayasu arteritis in Shanghai: A hospital-based study and systematic review.2021International journal of rheumatic diseases
  31. Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population.2021Joint bone spine
  32. Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis.2021Modern rheumatology
  33. Characteristics and Medium-term Outcomes of Takayasu Arteritis-related Renal Artery Stenosis: Analysis of a Large Chinese Cohort.2021The Journal of rheumatology
Chinese-language papers (not in the count)1
  1. [Recommendations of diagnosis and treatment of Takayasu's arteritis in China].2022Zhonghua nei ke za zhi
Earlier papers (2016–2020)22
  1. Involvement of the pulmonary arteries in patients with Takayasu arteritis: a prospective study from a single centre in China.2020Arthritis research & therapy
  2. Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery.2020Chinese medical journal
  3. Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review.2020Chinese medical journal
  4. CYR61/TGF-β axis promotes adventitial fibrosis of Takayasu's arteritis in the IL-17 mediated inflammatory microenvironment.2020Clinical and experimental rheumatology
  5. The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis.2020Clinical and experimental rheumatology
  6. The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up.2020Clinical rheumatology
  7. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort.2020Seminars in arthritis and rheumatism
  8. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex.2019Annals of the rheumatic diseases
  9. Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis.2019Arthritis research & therapy
  10. YKL-40 as a new biomarker of disease activity in Takayasu arteritis.2019International journal of cardiology
  11. Serum leptin, a potential predictor of long-term angiographic progression in Takayasu's arteritis.2019International journal of rheumatic diseases
  12. Radiology and biomarkers in assessing disease activity in Takayasu arteritis.2019International journal of rheumatic diseases
  13. Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis.2019Journal of autoimmunity
  14. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis.2018Clinical and experimental rheumatology
  15. Analysis of predictive factors for treatment resistance and disease relapse in Takayasu's arteritis.2018Clinical rheumatology
  16. 18F-FDG-PET/CT: an accurate method to assess the activity of Takayasu's arteritis.2018Clinical rheumatology
  17. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide.2018International journal of cardiology
  18. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.2017Rheumatology international
  19. The critical role of IL-6 in the pathogenesis of Takayasu arteritis.2016Clinical and experimental rheumatology
  20. Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis.2016Clinical rheumatology
  21. Celiac Artery Stenting in the Treatment of Intestinal Ischemia Due to the Sacrifice of the Dominant Inferior Mesenteric Artery During Endovascular Aortic Repair.2016Vascular and endovascular surgery
  22. [A comparative study of diagnostic efficacy of different diagnostic/ classification criteria in Takayasu arteritis].2016Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status8
  1. A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's ArteritisRecruitingNCT06498089Lead sponsorPhase 4Start 2024-06
  2. A Pilot Study in Severe Patients With Takayasu Arteritis.RecruitingNCT04300686Lead sponsorPhase 4Start 2020-03
  3. Comparison of Tofacitinib and Methotrexate in Takayasu's ArteritisStatus unknownNCT05102448Lead sponsorPhase 4Start 2021-11
  4. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsStatus unknownNCT04299971Lead sponsorPhase 4Start 2020-03
  5. Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery StenosisStatus unknownNCT04137614Lead sponsorN/AStart 2019-11
  6. The Registry Study of Takayasu Arteritis in East ChinaStatus unknownNCT03893136Lead sponsorStart 2016-11
  7. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Study sitePhase 3Start 2020-02
  8. Takayasu Arteritis Clinical Trial in ChinaCompletedNCT02981979Study siteN/AStart 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

26 hospitals in Shanghai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Shanghai for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

16 hospitals in Shanghai for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Shanghai for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

14 hospitals in Shanghai for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 002025

23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07203404

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrologyRadiology / nuclear medicine
Papers it led4
  1. Does Bi-exponential Fitting Perform better than Mono-exponential Fitting in IVIM-DWI? An Assessment of Renal Pathological Injury of IgA Nephropathy.2024Current medical imaging
  2. Serum soluble interleukin-2 receptor alpha may predict tubulointerstitial inflammatory cell infiltration and short-term disease progression in immunoglobin A nephropathy.2024Immunologic research
  3. Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status.2023BMC nephrology
  4. Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.2021Frontiers in immunology
Earlier papers (2016–2020)4
  1. Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.2020Nigerian journal of clinical practice
  2. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.2018Molecular medicine reports
  3. Elderly patients with glomerular diseases and IgA nephropathy.2017Nephrology (Carlton, Vic.)
  4. miR-382 Contributes to Renal Tubulointerstitial Fibrosis by Downregulating HSPD1.2017Oxidative medicine and cellular longevity
All its trials on ClinicalTrials.gov, any status4
  1. A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.RecruitingNCT07203404Study siteEarly phase 1Start 2025-07
  2. A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney DiseasesNot yet recruitingNCT07389499Study siteEarly phase 1Start 2027-08
  3. A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy SubjectsCompletedNCT07035665Study sitePhase 1Start 2025-06
  4. Comparison of HRS-5965 Capsules and Tablets in Healthy SubjectsCompletedNCT06490991Study sitePhase 1Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Shanghai for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

16 hospitals in Shanghai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Shanghai for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

复旦大学附属中山医院

Zhongshan Hospital, Fudan University

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Zhongshan Hospital; Zhongshan Hospital of Fudan University; Liver Cancer Institute and Zhongshan Hospital; Zhongshan Hospital Fudan University; Zhongshan Hospital (Xiamen); Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital and Shanghai Medical School; Liver Cancer Institute & Zhongshan Hospital

Suggest a correctionDownload the data